[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$finXH63M4TmXyKmzjYM8GKhTkw6loajskI8qVrMbdpmU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Gustave Roussy, Cancer Campus, Grand Paris",[4],239,false,72,62,110561,103,87,[14,17,20,23,25,28,30,32],{"name":15,"count":16},"Breast Cancer",14,{"name":18,"count":19},"Cancer",10,{"name":21,"count":22},"Prostate Cancer",6,{"name":24,"count":22},"Lung Cancer",{"name":26,"count":27},"Colorectal Cancer",5,{"name":29,"count":27},"Metastatic Cancer",{"name":31,"count":27},"Non Small Cell Lung Cancer",{"name":33,"count":34},"Head and Neck Cancer",4,[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT01887340","Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma","2016-06","Carboplatin",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT01837745","Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?","2022-04-01","rhTSH stimulation",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04823403","Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma","2022-11-04","Nivolumab",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06007092","Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer","2025-11","HPVDC injection level dose 1",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06508216","A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer","2025-12-17","Dato-DXd",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT03703050","Nivolumab for Pediatric and Adult Relapsing\u002FRefractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)","2026-04","Nivolumab cohort 1",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05215106","Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)","2026-06","Durvalumab",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06439888","Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer","2026-09","all-trans retinoic acid",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04221035","High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","2026-11","Vincristine",{"nctId":82,"briefTitle":83,"date":79,"intervention":84},"NCT04842162","Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery","indocyanine green",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,225,247,379,434,502,552,625,689,736,781,803,847,888,916,938,960,978,996,1014,1032,1050,1068,1086,1116,1141,1168,1186,1211,1229,1257,1282,1307,1330,1348,1377,1403,1421,1439,1465,1493,1547,1599,1655,1699,1721,1743,1788,1818,1844,1866,1896,1928,1950,1975,1993,2011,2029,2047,2065,2083,2101,2119,2137,2155,2173,2191,2209,2227,2245,2263,2281,2299,2317,2335,2353,2378,2401,2419,2444,2471,2492,2510,2528,2546,2564,2587,2605,2631,2657,2684,2715,2744,2762,2780,2798,2822,2847,2865,2890,2917,2942,2968,2993,3052,3098,3124,3158,3184,3215,3237,3259,3281,3313,3331,3349,3376,3394,3412,3437,3455,3479,3506,3524,3549,3575,3603,3621,3639,3657,3675,3699,3717,3735,3753,3776,3794,3818,3840,3858,3881,3921,3951,3986,4008,4030,4069,4105,4123,4150,4168,4191,4209,4235,4262,4280,4298,4321,4350,4368,4386,4404,4422,4440,4464,4488,4514,4532,4559,4583,4608,4632,4650,4668,4686,4704,4722,4740,4764,4782,4800,4826,4844,4866,4884,4902,4928,4956,4974,4992,5015,5040,5064,5082,5100,5118,5141,5166,5190,5208,5231,5255,5273,5291,5309,5334,5352,5370,5388,5406,5424,5448,5471,5489,5507,5525,5543,5561,5579,5597,5615,5638],{"intervention":50,"totalTrials":94,"cells":95},8,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":137,"PHASE3":193,"PHASE4":210,"NA":223},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":136,"soonestReadout":49},[101,111,124],{"nctId":47,"briefTitle":48,"status":102,"phases":103,"primaryCompletion":49,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":109},"RECRUITING",[87],"2024-11","2020-11-13",27,[108],"Hepatocellular Carcinoma",[50,110],"Ipilimumab",{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":122},"NCT04270864","Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers","TERMINATED",[87],"2021-07-13","2023-09-25","2020-04-10",25,[121],"Advanced Cancer",[110,50,123],"Tilsotolimod",{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":129,"completion":129,"start":130,"enrollment":98,"conditions":131,"interventions":133},"NCT03982121","Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy","WITHDRAWN",[87],"2020-02-12","2019-06-04",[132],"Colorectal Cancer Metastatic",[134,50,110,135],"FOLFOX regimen","GLA-SE",1,{"trials":138,"activeCount":192,"soonestReadout":186},[139,171,182],{"nctId":140,"briefTitle":141,"status":102,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":148},"NCT02813135","European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors",[87,88],"2031-02","2016-08-03",472,[147],"Pediatric Cancer",[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],"Ribociclib","Topotecan","Temozolomide","Everolimus","Adavosertib","Olaparib","Irinotecan","Vistusertib","Cyclophosphamide","Selumetinib","Enasidenib","Lirilumab","Fadraciclib","Cytarabine","Dexamethasone","Ceralasertib","Futibatinib","Capmatinib","Avelumab","Peposertib","Capivasertib","Vinorelbine",{"nctId":172,"briefTitle":173,"status":174,"phases":175,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":181},"NCT04267146","Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma","COMPLETED",[87,88],"2024-11-26","2019-07-15",41,[180],"High Grade Glioma",[50,151],{"nctId":183,"briefTitle":184,"status":102,"phases":185,"primaryCompletion":186,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":191},"NCT03406247","Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma",[88],"2027-11","2018-02-12",140,[190],"Head and Neck Squamous Cell Carcinoma",[50,110],2,{"trials":194,"activeCount":136,"soonestReadout":199},[195],{"nctId":196,"briefTitle":197,"status":102,"phases":198,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":205},"NCT06364631","CARE1 Pragmatic Clinical Trial",[89],"2032-05-05","2024-04-12",1250,[203,204],"Metastatic Kidney Cancer","Metastatic Kidney Carcinoma",[50,110,206,207,208,209],"Pembrolizumab","Cabozantinib","Axitinib","Lenvatinib",{"trials":211,"activeCount":136,"soonestReadout":216},[212],{"nctId":213,"briefTitle":214,"status":102,"phases":215,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":222},"NCT06934057","Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma",[90],"2028-04","2025-05-16",50,[220,221],"Kidney Cancer","Renal Cell Cancer",[50,207],{"trials":224,"activeCount":98},[],{"intervention":207,"totalTrials":192,"cells":226},{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":239,"NA":245},{"trials":228,"activeCount":98},[],{"trials":230,"activeCount":98},[],{"trials":232,"activeCount":98},[],{"trials":234,"activeCount":136,"soonestReadout":199},[235],{"nctId":196,"briefTitle":197,"status":102,"phases":236,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":237,"interventions":238},[89],[203,204],[50,110,206,207,208,209],{"trials":240,"activeCount":136,"soonestReadout":216},[241],{"nctId":213,"briefTitle":214,"status":102,"phases":242,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":243,"interventions":244},[90],[220,221],[50,207],{"trials":246,"activeCount":98},[],{"intervention":248,"totalTrials":249,"cells":250},"Cisplatin",9,{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":280,"PHASE3":320,"PHASE4":375,"NA":377},{"trials":252,"activeCount":98},[],{"trials":254,"activeCount":98},[255,268],{"nctId":256,"briefTitle":257,"status":174,"phases":258,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":266},"NCT02217956","Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma",[87],"2015-06","2011-06",30,[263,264,265],"Ovarian Adenocarcinoma","Fallopian Tube Adenocarcinoma","Primary Peritoneal Carcinoma",[248,267],"Bevacizumab",{"nctId":269,"briefTitle":270,"status":114,"phases":271,"primaryCompletion":272,"completion":273,"start":274,"enrollment":16,"conditions":275,"interventions":277},"NCT02997332","Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma",[87],"2020-03-17","2022-12-01","2017-03-30",[276],"Head and Neck Cancers",[70,278,248,279],"Docetaxel","5 Fluorouracil",{"trials":281,"activeCount":192,"soonestReadout":39},[282,300,308],{"nctId":283,"briefTitle":284,"status":102,"phases":285,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":292},"NCT07001618","Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer",[88],"2030-09","2032-09","2025-11-17",162,[291],"NSCLC (Advanced Non-small Cell Lung Cancer)",[293,294,248,295,296,267,297,298,278,299,170],"MaaT033","Cemiplimab","Carboplatine","Pemetrexed","Paclitaxel","gemcitabine","Vinorelbine i.v. 25 mg\u002Fm²",{"nctId":37,"briefTitle":38,"status":102,"phases":301,"primaryCompletion":39,"completion":69,"start":302,"enrollment":303,"conditions":304,"interventions":306},[88],"2013-06",271,[305],"Seminoma",[40,307,248],"Etoposide",{"nctId":309,"briefTitle":310,"status":174,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":318},"NCT03612791","Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab",[88],"2024-02-26","2025-05-13","2018-08-13",189,[317],"Locally Advanced Cervical Cancer",[319,248],"Atezolizumab",{"trials":321,"activeCount":136,"soonestReadout":79},[322,341,352,365],{"nctId":77,"briefTitle":78,"status":102,"phases":323,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":330},[89],"2032-11","2019-11-05",800,[328,329],"High-Risk Neuroblastoma","Patient With Insufficient Response Chemoimmunotherapy",[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],"Vindesine","Dacarbazine","Ifosfamide","Doxorubicin","Busulfan","Melphalan","Thiotepa","Dinutuximab Beta","Temozolomide 100 MG","Cyclophosphamid",{"nctId":342,"briefTitle":343,"status":344,"phases":345,"start":346,"enrollment":347,"conditions":348,"interventions":350},"NCT00126269","Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary","UNKNOWN",[89],"2003-05",192,[349],"Carcinoma",[351,298],"cisplatin",{"nctId":353,"briefTitle":354,"status":174,"phases":355,"primaryCompletion":356,"start":357,"enrollment":358,"conditions":359,"interventions":360},"NCT00002823","Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer",[89],"2001-01","1995-02",3300,[24],[351,361,362,363,364],"etoposide","vinblastine sulfate","vindesine","vinorelbine tartrate",{"nctId":366,"briefTitle":367,"status":344,"phases":368,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT00002858","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer",[89],"1993-03",280,[24],[351,373,374,361],"cyclophosphamide","doxorubicin hydrochloride",{"trials":376,"activeCount":98},[],{"trials":378,"activeCount":98},[],{"intervention":110,"totalTrials":380,"cells":381},7,{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":409,"PHASE3":424,"PHASE4":430,"NA":432},{"trials":383,"activeCount":98},[],{"trials":385,"activeCount":136,"soonestReadout":49},[386,390,394,398],{"nctId":47,"briefTitle":48,"status":102,"phases":387,"primaryCompletion":49,"completion":104,"start":105,"enrollment":106,"conditions":388,"interventions":389},[87],[108],[50,110],{"nctId":112,"briefTitle":113,"status":114,"phases":391,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":392,"interventions":393},[87],[121],[110,50,123],{"nctId":125,"briefTitle":126,"status":127,"phases":395,"primaryCompletion":129,"completion":129,"start":130,"enrollment":98,"conditions":396,"interventions":397},[87],[132],[134,50,110,135],{"nctId":399,"briefTitle":400,"status":114,"phases":401,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":406,"interventions":408},"NCT01557114","Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma",[87],"2015-11","2016-03","2011-03",19,[407],"Malignant Melanoma",[110],{"trials":410,"activeCount":136,"soonestReadout":186},[411,420],{"nctId":412,"briefTitle":413,"status":174,"phases":414,"primaryCompletion":415,"completion":415,"start":416,"enrollment":34,"conditions":417,"interventions":419},"NCT02094391","Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma",[88],"2016-02","2014-03",[418],"In-transit Metastases Melanoma Stage IIIB and IIIC",[110],{"nctId":183,"briefTitle":184,"status":102,"phases":421,"primaryCompletion":186,"completion":186,"start":187,"enrollment":188,"conditions":422,"interventions":423},[88],[190],[50,110],{"trials":425,"activeCount":136,"soonestReadout":199},[426],{"nctId":196,"briefTitle":197,"status":102,"phases":427,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":428,"interventions":429},[89],[203,204],[50,110,206,207,208,209],{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":98},[],{"intervention":154,"totalTrials":27,"cells":435},{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":484,"PHASE4":498,"NA":500},{"trials":437,"activeCount":98},[],{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":192,"soonestReadout":446},[442,457,461,471],{"nctId":443,"briefTitle":444,"status":102,"phases":445,"primaryCompletion":446,"completion":447,"start":448,"enrollment":449,"conditions":450,"interventions":455},"NCT06298084","Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd",[87,88],"2027-09","2029-06","2024-03-21",152,[451,452,453,454],"Breast Cancer Metastatic","HER2-positive Metastatic Breast Cancer","HER2 Low Breast Carcinoma","Advanced Breast Cancer",[456,154],"Patritumab deruxtecan",{"nctId":140,"briefTitle":141,"status":102,"phases":458,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":459,"interventions":460},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"nctId":462,"briefTitle":463,"status":114,"phases":464,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":470},"NCT02679963","Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer",[88],"2020-12-22","2022-03-25","2016-02-05",180,[31],[154],{"nctId":472,"briefTitle":473,"status":114,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":480},"NCT04826198","Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months",[87,88],"2024-04-04","2020-10-05",13,[479],"Ovarian Cancer",[481,482,154,483],"AsiDNA","Niraparib","Rucaparib",{"trials":485,"activeCount":136,"soonestReadout":490},[486],{"nctId":487,"briefTitle":488,"status":102,"phases":489,"primaryCompletion":490,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":497},"NCT06712472","Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer",[89],"2030-06","2031-12","2024-06-26",554,[495,496],"Endometrial Cancer","p53abn",[154],{"trials":499,"activeCount":98},[],{"trials":501,"activeCount":98},[],{"intervention":40,"totalTrials":27,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":532,"PHASE3":542,"PHASE4":548,"NA":550},{"trials":505,"activeCount":98},[],{"trials":507,"activeCount":98},[508,519],{"nctId":509,"briefTitle":510,"status":174,"phases":511,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":517},"NCT02515877","Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers",[87],"2013-04","2008-01",15,[516],"Cervical Cancer",[518,40],"Vistide",{"nctId":520,"briefTitle":521,"status":344,"phases":522,"primaryCompletion":523,"start":524,"enrollment":525,"conditions":526,"interventions":528},"NCT00811408","Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy",[87],"2009-10","2008-04",24,[516,527],"Precancerous Condition",[529,530,531],"carboplatin","cidofovir","protein expression analysis",{"trials":533,"activeCount":192,"soonestReadout":39},[534,538],{"nctId":37,"briefTitle":38,"status":102,"phases":535,"primaryCompletion":39,"completion":69,"start":302,"enrollment":303,"conditions":536,"interventions":537},[88],[305],[40,307,248],{"nctId":140,"briefTitle":141,"status":102,"phases":539,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":540,"interventions":541},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":543,"activeCount":136,"soonestReadout":79},[544],{"nctId":77,"briefTitle":78,"status":102,"phases":545,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":546,"interventions":547},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"trials":549,"activeCount":98},[],{"trials":551,"activeCount":98},[],{"intervention":206,"totalTrials":22,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":581,"PHASE3":615,"PHASE4":621,"NA":623},{"trials":555,"activeCount":98},[],{"trials":557,"activeCount":98},[558,569],{"nctId":559,"briefTitle":560,"status":174,"phases":561,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":567},"NCT03596281","Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer",[87],"2021-03-11","2023-04-11","2018-12-05",47,[479],[206,267,568],"pegylated liposomal doxorubicin",{"nctId":570,"briefTitle":571,"status":174,"phases":572,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":579},"NCT02856425","Trial Of Pembrolizumab And Nintedanib",[87],"2025-01-10","2026-01-10","2016-11-10",196,[578],"Patients With Any Advanced Solid Tumors",[580,206],"Nintedanib",{"trials":582,"activeCount":136,"soonestReadout":588},[583,595,605],{"nctId":584,"briefTitle":585,"status":586,"phases":587,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":594},"NCT03313206","Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma","ACTIVE_NOT_RECRUITING",[88],"2027-01","2029-01","2018-05-28",60,[593],"Head and Neck Mucosal Melanomas",[206,209],{"nctId":596,"briefTitle":597,"status":127,"phases":598,"primaryCompletion":599,"completion":447,"start":600,"enrollment":98,"conditions":601,"interventions":602},"NCT06116578","Study Evaluating Pembrolizumab +\u002F- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab",[88],"2027-07","2025-01-01",[18],[206,603,604],"Pembrolizumab and Olaparib","Pembrolizumab adjuvant",{"nctId":606,"briefTitle":607,"status":174,"phases":608,"primaryCompletion":609,"completion":610,"start":611,"enrollment":178,"conditions":612,"interventions":614},"NCT03212651","Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab",[88],"2019-07-18","2019-12-13","2017-10-17",[613],"Bladder Cancer",[206],{"trials":616,"activeCount":136,"soonestReadout":199},[617],{"nctId":196,"briefTitle":197,"status":102,"phases":618,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":619,"interventions":620},[89],[203,204],[50,110,206,207,208,209],{"trials":622,"activeCount":98},[],{"trials":624,"activeCount":98},[],{"intervention":152,"totalTrials":27,"cells":626},{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":643,"PHASE3":670,"PHASE4":685,"NA":687},{"trials":628,"activeCount":98},[],{"trials":630,"activeCount":98},[631],{"nctId":632,"briefTitle":633,"status":174,"phases":634,"primaryCompletion":635,"completion":636,"start":637,"enrollment":638,"conditions":639,"interventions":642},"NCT01167530","Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer",[87],"2013-07-04","2017-02-09","2008-02-26",26,[640,641],"Non-small Cell Lung Cancer","Locally Advanced Disease",[152],{"trials":644,"activeCount":136,"soonestReadout":143},[645,654,658],{"nctId":646,"briefTitle":647,"status":114,"phases":648,"primaryCompletion":649,"completion":649,"start":650,"enrollment":651,"conditions":652,"interventions":653},"NCT01888042","Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer",[88],"2014-07","2011-07",61,[220],[152],{"nctId":140,"briefTitle":141,"status":102,"phases":655,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":656,"interventions":657},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"nctId":659,"briefTitle":660,"status":344,"phases":661,"primaryCompletion":662,"completion":662,"start":663,"enrollment":664,"conditions":665,"interventions":667},"NCT02233049","Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication",[88],"2018-10","2014-10",250,[666],"Diffuse Intrinsic Pontine Glioma",[668,152,669],"Erlotinib","Dasatinib",{"trials":671,"activeCount":136,"soonestReadout":676},[672],{"nctId":673,"briefTitle":674,"status":102,"phases":675,"primaryCompletion":676,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":683},"NCT05476939","Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0",[89],"2028-09","2031-09","2022-09-29",433,[666,681,682],"Diffuse Midline Glioma, H3 K27M-Mutant","Diffuse Midline Glioma, H3K27-altered",[152,684],"ONC201",{"trials":686,"activeCount":98},[],{"trials":688,"activeCount":98},[],{"intervention":361,"totalTrials":27,"cells":690},{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":701,"PHASE4":732,"NA":734},{"trials":692,"activeCount":98},[],{"trials":694,"activeCount":98},[],{"trials":696,"activeCount":136,"soonestReadout":39},[697],{"nctId":37,"briefTitle":38,"status":102,"phases":698,"primaryCompletion":39,"completion":69,"start":302,"enrollment":303,"conditions":699,"interventions":700},[88],[305],[40,307,248],{"trials":702,"activeCount":136,"soonestReadout":79},[703,707,724,728],{"nctId":77,"briefTitle":78,"status":102,"phases":704,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":705,"interventions":706},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"nctId":708,"briefTitle":709,"status":174,"phases":710,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT00006455","Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)",[89],"2009-01-12","2020-09-03","1999-11-26",885,[716],"Lymphoma",[373,718,719,374,361,720,721,722,723,362],"cytarabine","dexamethasone","ifosfamide","leucovorin calcium","methotrexate","therapeutic hydrocortisone",{"nctId":353,"briefTitle":354,"status":174,"phases":725,"primaryCompletion":356,"start":357,"enrollment":358,"conditions":726,"interventions":727},[89],[24],[351,361,362,363,364],{"nctId":366,"briefTitle":367,"status":344,"phases":729,"start":369,"enrollment":370,"conditions":730,"interventions":731},[89],[24],[351,373,374,361],{"trials":733,"activeCount":98},[],{"trials":735,"activeCount":98},[],{"intervention":155,"totalTrials":34,"cells":737},{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":757,"PHASE4":777,"NA":779},{"trials":739,"activeCount":98},[],{"trials":741,"activeCount":98},[],{"trials":743,"activeCount":136,"soonestReadout":143},[744,753],{"nctId":745,"briefTitle":746,"status":174,"phases":747,"primaryCompletion":415,"completion":415,"start":748,"enrollment":19,"conditions":749,"interventions":751},"NCT01677884","Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy",[88],"2012-11",[750],"Colorectal Neoplasms",[267,752,155],"Capecitabine",{"nctId":140,"briefTitle":141,"status":102,"phases":754,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":755,"interventions":756},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":758,"activeCount":136,"soonestReadout":79},[759,773],{"nctId":760,"briefTitle":761,"status":174,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":768},"NCT00126256","Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer",[89],"2006-02","2002-02",570,[26,767],"Metastasis",[769,770,771,772],"5-fluorouracil","leucovorin","irinotecan","oxaliplatin",{"nctId":77,"briefTitle":78,"status":102,"phases":774,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":775,"interventions":776},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"trials":778,"activeCount":98},[],{"trials":780,"activeCount":98},[],{"intervention":209,"totalTrials":192,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":793,"PHASE4":799,"NA":801},{"trials":784,"activeCount":98},[],{"trials":786,"activeCount":98},[],{"trials":788,"activeCount":136,"soonestReadout":588},[789],{"nctId":584,"briefTitle":585,"status":586,"phases":790,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":791,"interventions":792},[88],[593],[206,209],{"trials":794,"activeCount":136,"soonestReadout":199},[795],{"nctId":196,"briefTitle":197,"status":102,"phases":796,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":797,"interventions":798},[89],[203,204],[50,110,206,207,208,209],{"trials":800,"activeCount":98},[],{"trials":802,"activeCount":98},[],{"intervention":337,"totalTrials":804,"cells":805},3,{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":837,"PHASE4":843,"NA":845},{"trials":807,"activeCount":98},[],{"trials":809,"activeCount":98},[],{"trials":811,"activeCount":98},[812,826],{"nctId":813,"briefTitle":814,"status":114,"phases":815,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":819,"interventions":821},"NCT02025881","Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma",[87,88],"2020-10-25","2013-09-14",29,[820],"High-risk Medulloblastoma",[822,337,823,824,825,151],"Carboplatin + etoposide","Cyclophosphamide + Busilvex","Temozolimide + Irinotecan","Etoposide + radiotherapy",{"nctId":827,"briefTitle":828,"status":114,"phases":829,"primaryCompletion":830,"completion":831,"start":832,"enrollment":833,"conditions":834,"interventions":836},"NCT03165292","Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction",[88],"2023-08-28","2024-03-28","2018-10-01",34,[835],"Very High Risk Neuroblastoma",[150,337],{"trials":838,"activeCount":136,"soonestReadout":79},[839],{"nctId":77,"briefTitle":78,"status":102,"phases":840,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":841,"interventions":842},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"trials":844,"activeCount":98},[],{"trials":846,"activeCount":98},[],{"intervention":334,"totalTrials":804,"cells":848},{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":868,"PHASE4":884,"NA":886},{"trials":850,"activeCount":98},[],{"trials":852,"activeCount":98},[],{"trials":854,"activeCount":98},[855],{"nctId":856,"briefTitle":857,"status":174,"phases":858,"primaryCompletion":859,"completion":860,"start":861,"enrollment":862,"conditions":863,"interventions":866},"NCT02131480","Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma",[88],"2013-01","2016-10","2010-06",110,[864,865],"Uterus Leiomyosarcoma","Soft Tissue Leiomyosarcoma",[334,867],"Trabectedin",{"trials":869,"activeCount":136,"soonestReadout":79},[870,874],{"nctId":77,"briefTitle":78,"status":102,"phases":871,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":872,"interventions":873},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"nctId":875,"briefTitle":876,"status":174,"phases":877,"primaryCompletion":878,"completion":878,"start":879,"enrollment":880,"conditions":881,"interventions":883},"NCT02997358","Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma",[89],"2021-07-28","2017-01-18",150,[882],"Uterine or Soft Tissue Leiomyosarcoma",[334,867],{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":98},[],{"intervention":336,"totalTrials":192,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":906,"PHASE4":912,"NA":914},{"trials":891,"activeCount":98},[],{"trials":893,"activeCount":98},[],{"trials":895,"activeCount":98},[896],{"nctId":897,"briefTitle":898,"status":344,"phases":899,"start":900,"enrollment":901,"conditions":902,"interventions":904},"NCT00181025","Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle",[88],"2004-05",33,[903],"Sarcoma of Pelvis",[905,336],"Tasonermine",{"trials":907,"activeCount":136,"soonestReadout":79},[908],{"nctId":77,"briefTitle":78,"status":102,"phases":909,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":910,"interventions":911},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"trials":913,"activeCount":98},[],{"trials":915,"activeCount":98},[],{"intervention":331,"totalTrials":192,"cells":917},{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":922,"PHASE3":924,"PHASE4":934,"NA":936},{"trials":919,"activeCount":98},[],{"trials":921,"activeCount":98},[],{"trials":923,"activeCount":98},[],{"trials":925,"activeCount":136,"soonestReadout":79},[926,930],{"nctId":77,"briefTitle":78,"status":102,"phases":927,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":928,"interventions":929},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"nctId":353,"briefTitle":354,"status":174,"phases":931,"primaryCompletion":356,"start":357,"enrollment":358,"conditions":932,"interventions":933},[89],[24],[351,361,362,363,364],{"trials":935,"activeCount":98},[],{"trials":937,"activeCount":98},[],{"intervention":333,"totalTrials":192,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":946,"PHASE4":956,"NA":958},{"trials":941,"activeCount":98},[],{"trials":943,"activeCount":98},[],{"trials":945,"activeCount":98},[],{"trials":947,"activeCount":136,"soonestReadout":79},[948,952],{"nctId":77,"briefTitle":78,"status":102,"phases":949,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":950,"interventions":951},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"nctId":708,"briefTitle":709,"status":174,"phases":953,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":954,"interventions":955},[89],[716],[373,718,719,374,361,720,721,722,723,362],{"trials":957,"activeCount":98},[],{"trials":959,"activeCount":98},[],{"intervention":80,"totalTrials":136,"cells":961},{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":966,"PHASE3":968,"PHASE4":974,"NA":976},{"trials":963,"activeCount":98},[],{"trials":965,"activeCount":98},[],{"trials":967,"activeCount":98},[],{"trials":969,"activeCount":136,"soonestReadout":79},[970],{"nctId":77,"briefTitle":78,"status":102,"phases":971,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":972,"interventions":973},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[],{"intervention":332,"totalTrials":136,"cells":979},{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":992,"NA":994},{"trials":981,"activeCount":98},[],{"trials":983,"activeCount":98},[],{"trials":985,"activeCount":98},[],{"trials":987,"activeCount":136,"soonestReadout":79},[988],{"nctId":77,"briefTitle":78,"status":102,"phases":989,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":990,"interventions":991},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"trials":993,"activeCount":98},[],{"trials":995,"activeCount":98},[],{"intervention":335,"totalTrials":136,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1010,"NA":1012},{"trials":999,"activeCount":98},[],{"trials":1001,"activeCount":98},[],{"trials":1003,"activeCount":98},[],{"trials":1005,"activeCount":136,"soonestReadout":79},[1006],{"nctId":77,"briefTitle":78,"status":102,"phases":1007,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":1008,"interventions":1009},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"trials":1011,"activeCount":98},[],{"trials":1013,"activeCount":98},[],{"intervention":338,"totalTrials":136,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1028,"NA":1030},{"trials":1017,"activeCount":98},[],{"trials":1019,"activeCount":98},[],{"trials":1021,"activeCount":98},[],{"trials":1023,"activeCount":136,"soonestReadout":79},[1024],{"nctId":77,"briefTitle":78,"status":102,"phases":1025,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":1026,"interventions":1027},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"trials":1029,"activeCount":98},[],{"trials":1031,"activeCount":98},[],{"intervention":339,"totalTrials":136,"cells":1033},{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1040,"PHASE4":1046,"NA":1048},{"trials":1035,"activeCount":98},[],{"trials":1037,"activeCount":98},[],{"trials":1039,"activeCount":98},[],{"trials":1041,"activeCount":136,"soonestReadout":79},[1042],{"nctId":77,"briefTitle":78,"status":102,"phases":1043,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":1044,"interventions":1045},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"trials":1047,"activeCount":98},[],{"trials":1049,"activeCount":98},[],{"intervention":340,"totalTrials":136,"cells":1051},{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1058,"PHASE4":1064,"NA":1066},{"trials":1053,"activeCount":98},[],{"trials":1055,"activeCount":98},[],{"trials":1057,"activeCount":98},[],{"trials":1059,"activeCount":136,"soonestReadout":79},[1060],{"nctId":77,"briefTitle":78,"status":102,"phases":1061,"primaryCompletion":79,"completion":324,"start":325,"enrollment":326,"conditions":1062,"interventions":1063},[89],[328,329],[80,40,307,331,332,333,334,335,336,337,338,248,339,155,340],{"trials":1065,"activeCount":98},[],{"trials":1067,"activeCount":98},[],{"intervention":684,"totalTrials":136,"cells":1069},{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1076,"PHASE4":1082,"NA":1084},{"trials":1071,"activeCount":98},[],{"trials":1073,"activeCount":98},[],{"trials":1075,"activeCount":98},[],{"trials":1077,"activeCount":136,"soonestReadout":676},[1078],{"nctId":673,"briefTitle":674,"status":102,"phases":1079,"primaryCompletion":676,"completion":677,"start":678,"enrollment":679,"conditions":1080,"interventions":1081},[89],[666,681,682],[152,684],{"trials":1083,"activeCount":98},[],{"trials":1085,"activeCount":98},[],{"intervention":1087,"totalTrials":136,"cells":1088},"HPV vaccine",{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1095,"PHASE4":1112,"NA":1114},{"trials":1090,"activeCount":98},[],{"trials":1092,"activeCount":98},[],{"trials":1094,"activeCount":98},[],{"trials":1096,"activeCount":136,"soonestReadout":1102},[1097],{"nctId":1098,"briefTitle":1099,"status":1100,"phases":1101,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":1105,"interventions":1111},"NCT07431502","Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions","NOT_YET_RECRUITING",[89],"2030-11","2026-05",984,[1106,1107,1108,1109,1110],"Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Vulvar Site","Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Vaginal Site","Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Penile Site","Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Cervical Site","Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Anal Site",[1087],{"trials":1113,"activeCount":98},[],{"trials":1115,"activeCount":98},[],{"intervention":1117,"totalTrials":136,"cells":1118},"SoC-based immunotherapy",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1137,"NA":1139},{"trials":1120,"activeCount":98},[],{"trials":1122,"activeCount":98},[],{"trials":1124,"activeCount":98},[],{"trials":1126,"activeCount":136,"soonestReadout":1131},[1127],{"nctId":1128,"briefTitle":1129,"status":102,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1136},"NCT06840782","First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.",[89],"2030-02","2025-09-09",124,[1135],"Oligometastatic Non-small Cell Lung Cancer (NSCLC)",[1117],{"trials":1138,"activeCount":98},[],{"trials":1140,"activeCount":98},[],{"intervention":1142,"totalTrials":136,"cells":1143},"Venetoclax",{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1150,"PHASE4":1164,"NA":1166},{"trials":1145,"activeCount":98},[],{"trials":1147,"activeCount":98},[],{"trials":1149,"activeCount":98},[],{"trials":1151,"activeCount":136,"soonestReadout":286},[1152],{"nctId":1153,"briefTitle":1154,"status":1100,"phases":1155,"primaryCompletion":286,"completion":1156,"start":1157,"enrollment":1158,"conditions":1159,"interventions":1162},"NCT07082452","A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction",[89],"2031-03","2025-09",262,[1160,1161],"Leukemia, B-Cell, Chronic","Leukemia",[1142,1163],"Azacitidine",{"trials":1165,"activeCount":98},[],{"trials":1167,"activeCount":98},[],{"intervention":1163,"totalTrials":136,"cells":1169},{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1174,"PHASE3":1176,"PHASE4":1182,"NA":1184},{"trials":1171,"activeCount":98},[],{"trials":1173,"activeCount":98},[],{"trials":1175,"activeCount":98},[],{"trials":1177,"activeCount":136,"soonestReadout":286},[1178],{"nctId":1153,"briefTitle":1154,"status":1100,"phases":1179,"primaryCompletion":286,"completion":1156,"start":1157,"enrollment":1158,"conditions":1180,"interventions":1181},[89],[1160,1161],[1142,1163],{"trials":1183,"activeCount":98},[],{"trials":1185,"activeCount":98},[],{"intervention":1187,"totalTrials":136,"cells":1188},"Acetylsalicylic acid",{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1207,"NA":1209},{"trials":1190,"activeCount":98},[],{"trials":1192,"activeCount":98},[],{"trials":1194,"activeCount":98},[],{"trials":1196,"activeCount":136,"soonestReadout":1201},[1197],{"nctId":1198,"briefTitle":1199,"status":102,"phases":1200,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1205},"NCT03819101","Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer",[89],"2042-03","2019-06-06",1210,[21],[1187,1206],"Atorvastatin",{"trials":1208,"activeCount":98},[],{"trials":1210,"activeCount":98},[],{"intervention":1206,"totalTrials":136,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1219,"PHASE4":1225,"NA":1227},{"trials":1214,"activeCount":98},[],{"trials":1216,"activeCount":98},[],{"trials":1218,"activeCount":98},[],{"trials":1220,"activeCount":136,"soonestReadout":1201},[1221],{"nctId":1198,"briefTitle":1199,"status":102,"phases":1222,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":1223,"interventions":1224},[89],[21],[1187,1206],{"trials":1226,"activeCount":98},[],{"trials":1228,"activeCount":98},[],{"intervention":1230,"totalTrials":136,"cells":1231},"Tislelizumab",{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1238,"PHASE4":1253,"NA":1255},{"trials":1233,"activeCount":98},[],{"trials":1235,"activeCount":98},[],{"trials":1237,"activeCount":98},[],{"trials":1239,"activeCount":136,"soonestReadout":1244},[1240],{"nctId":1241,"briefTitle":1242,"status":102,"phases":1243,"primaryCompletion":1244,"completion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1252},"NCT06332274","tislelizUMaB in canceR Patients With molEcuLar residuaL Disease",[89],"2029-04","2030-04","2025-04-16",717,[18,24,1249,1250,1251],"Colo-rectal Cancer","Pancreas Cancer","Soft Tissue Sarcoma",[1230],{"trials":1254,"activeCount":98},[],{"trials":1256,"activeCount":98},[],{"intervention":1258,"totalTrials":136,"cells":1259},"Adjuvant chemotherapy with Capecitabine-Temozolomide",{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1266,"PHASE4":1278,"NA":1280},{"trials":1261,"activeCount":98},[],{"trials":1263,"activeCount":98},[],{"trials":1265,"activeCount":98},[],{"trials":1267,"activeCount":136,"soonestReadout":1272},[1268],{"nctId":1269,"briefTitle":1270,"status":1100,"phases":1271,"primaryCompletion":1272,"completion":1272,"start":74,"enrollment":1273,"conditions":1274,"interventions":1277},"NCT07591493","Adjuvant Trial in Pancreatic Neuroendocrine Tumors",[89],"2035-06",300,[1275,1276],"Pancreatic Neuroendocrine Tumors (pNET)","Pancreatic Neuroendocrine Tumors",[1258],{"trials":1279,"activeCount":98},[],{"trials":1281,"activeCount":98},[],{"intervention":1283,"totalTrials":136,"cells":1284},"Thromboprophylaxis",{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1291,"PHASE4":1303,"NA":1305},{"trials":1286,"activeCount":98},[],{"trials":1288,"activeCount":98},[],{"trials":1290,"activeCount":98},[],{"trials":1292,"activeCount":136,"soonestReadout":1297},[1293],{"nctId":1294,"briefTitle":1295,"status":102,"phases":1296,"primaryCompletion":1297,"completion":1297,"start":1298,"enrollment":1299,"conditions":1300,"interventions":1302},"NCT05874063","Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors",[89],"2028-02","2023-10-17",387,[1301],"Germ Cell Tumor",[1283],{"trials":1304,"activeCount":98},[],{"trials":1306,"activeCount":98},[],{"intervention":45,"totalTrials":136,"cells":1308},{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1326,"NA":1328},{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[],{"trials":1316,"activeCount":136,"soonestReadout":44},[1317],{"nctId":42,"briefTitle":43,"status":586,"phases":1318,"primaryCompletion":44,"completion":1319,"start":1320,"enrollment":1321,"conditions":1322,"interventions":1324},[89],"2030-01-01","2013-05-13",776,[1323],"Low Risk Differentiated Thyroid Cancer",[45,1325],"I131",{"trials":1327,"activeCount":98},[],{"trials":1329,"activeCount":98},[],{"intervention":1325,"totalTrials":136,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1344,"NA":1346},{"trials":1333,"activeCount":98},[],{"trials":1335,"activeCount":98},[],{"trials":1337,"activeCount":98},[],{"trials":1339,"activeCount":136,"soonestReadout":44},[1340],{"nctId":42,"briefTitle":43,"status":586,"phases":1341,"primaryCompletion":44,"completion":1319,"start":1320,"enrollment":1321,"conditions":1342,"interventions":1343},[89],[1323],[45,1325],{"trials":1345,"activeCount":98},[],{"trials":1347,"activeCount":98},[],{"intervention":1349,"totalTrials":136,"cells":1350},"CBD oil",{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1357,"PHASE4":1373,"NA":1375},{"trials":1352,"activeCount":98},[],{"trials":1354,"activeCount":98},[],{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":136,"soonestReadout":1363},[1359],{"nctId":1360,"briefTitle":1361,"status":1100,"phases":1362,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":1365,"conditions":1366,"interventions":1372},"NCT06787118","Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer",[89],"2027-05","2025-12",130,[1367,1368,1369,1370,1371],"Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III","HR+ Breast Cancer","AI-related Musculoskeletal Pain",[1349],{"trials":1374,"activeCount":98},[],{"trials":1376,"activeCount":98},[],{"intervention":1378,"totalTrials":136,"cells":1379},"Pembrolizumab 200 mg Q6W",{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1399,"NA":1401},{"trials":1381,"activeCount":98},[],{"trials":1383,"activeCount":98},[],{"trials":1385,"activeCount":98},[],{"trials":1387,"activeCount":136,"soonestReadout":589},[1388],{"nctId":1389,"briefTitle":1390,"status":102,"phases":1391,"primaryCompletion":589,"completion":589,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1396},"NCT05692999","Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study",[89],"2023-03-20",1166,[1395],"Metastatic Non-squamous Lung Cancer",[1378,1397,1398],"Pemetrexed 500 mg\u002Fm^2 Q3W","Pembrolizumab 200 mg Q3W or 400 mg Q6W",{"trials":1400,"activeCount":98},[],{"trials":1402,"activeCount":98},[],{"intervention":1397,"totalTrials":136,"cells":1404},{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1411,"PHASE4":1417,"NA":1419},{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[],{"trials":1410,"activeCount":98},[],{"trials":1412,"activeCount":136,"soonestReadout":589},[1413],{"nctId":1389,"briefTitle":1390,"status":102,"phases":1414,"primaryCompletion":589,"completion":589,"start":1392,"enrollment":1393,"conditions":1415,"interventions":1416},[89],[1395],[1378,1397,1398],{"trials":1418,"activeCount":98},[],{"trials":1420,"activeCount":98},[],{"intervention":1398,"totalTrials":136,"cells":1422},{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1435,"NA":1437},{"trials":1424,"activeCount":98},[],{"trials":1426,"activeCount":98},[],{"trials":1428,"activeCount":98},[],{"trials":1430,"activeCount":136,"soonestReadout":589},[1431],{"nctId":1389,"briefTitle":1390,"status":102,"phases":1432,"primaryCompletion":589,"completion":589,"start":1392,"enrollment":1393,"conditions":1433,"interventions":1434},[89],[1395],[1378,1397,1398],{"trials":1436,"activeCount":98},[],{"trials":1438,"activeCount":98},[],{"intervention":1440,"totalTrials":136,"cells":1441},"Experimental",{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1461,"NA":1463},{"trials":1443,"activeCount":98},[],{"trials":1445,"activeCount":98},[],{"trials":1447,"activeCount":98},[],{"trials":1449,"activeCount":136,"soonestReadout":1454},[1450],{"nctId":1451,"briefTitle":1452,"status":1100,"phases":1453,"primaryCompletion":1454,"completion":1455,"start":74,"enrollment":1456,"conditions":1457,"interventions":1460},"NCT07591467","Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer",[89],"2036-09","2036-12",330,[1458,1459,21],"BRCA-Mutated","Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer",[1440],{"trials":1462,"activeCount":98},[],{"trials":1464,"activeCount":98},[],{"intervention":208,"totalTrials":192,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1479,"NA":1481},{"trials":1468,"activeCount":98},[],{"trials":1470,"activeCount":98},[],{"trials":1472,"activeCount":98},[],{"trials":1474,"activeCount":136,"soonestReadout":199},[1475],{"nctId":196,"briefTitle":197,"status":102,"phases":1476,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":1477,"interventions":1478},[89],[203,204],[50,110,206,207,208,209],{"trials":1480,"activeCount":98},[],{"trials":1482,"activeCount":98},[1483],{"nctId":1484,"briefTitle":1485,"status":174,"phases":1486,"primaryCompletion":512,"completion":1487,"start":1488,"enrollment":106,"conditions":1489,"interventions":1491},"NCT01486251","Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer",[91],"2014-09","2011-09",[1490],"Colorectal Carcinoma",[1492],"axitinib",{"intervention":752,"totalTrials":34,"cells":1494},{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1513,"PHASE3":1541,"PHASE4":1543,"NA":1545},{"trials":1496,"activeCount":98},[],{"trials":1498,"activeCount":136,"soonestReadout":1503},[1499],{"nctId":1500,"briefTitle":1501,"status":102,"phases":1502,"primaryCompletion":1503,"completion":589,"start":1504,"enrollment":1505,"conditions":1506,"interventions":1508},"NCT05912075","Preoperative Radiotherapy And ASTX660 in Rectum Cancer",[87],"2028-01-01","2023-12-19",78,[1507],"Locally-advanced Rectal Cancer",[1509,752,1510,1511,1512],"mFOLFIRINOX","TOLINAPANT","FOLFOX4","CAPOX",{"trials":1514,"activeCount":192,"soonestReadout":1534},[1515,1519,1530],{"nctId":745,"briefTitle":746,"status":174,"phases":1516,"primaryCompletion":415,"completion":415,"start":748,"enrollment":19,"conditions":1517,"interventions":1518},[88],[750],[267,752,155],{"nctId":1520,"briefTitle":1521,"status":1100,"phases":1522,"primaryCompletion":589,"completion":1523,"start":1524,"enrollment":525,"conditions":1525,"interventions":1527},"NCT07622017","KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer",[88],"2030-07","2026-07",[1526],"Rectal Cancer",[1528,752,1512,1529],"KRC-01","FOLFOX",{"nctId":1531,"briefTitle":1532,"status":586,"phases":1533,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":188,"conditions":1536,"interventions":1538},"NCT03351296","Two Chemotherapy Regimens Plus or Minus Bevacizumab",[88],"2028-12","2018-06-26",[1537],"Pancreatic Cancer",[1539,1540,752,151,267],"LV5FU2","Streptozocin",{"trials":1542,"activeCount":98},[],{"trials":1544,"activeCount":98},[],{"trials":1546,"activeCount":98},[],{"intervention":267,"totalTrials":380,"cells":1548},{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1561,"PHASE3":1593,"PHASE4":1595,"NA":1597},{"trials":1550,"activeCount":98},[],{"trials":1552,"activeCount":98},[1553,1557],{"nctId":559,"briefTitle":560,"status":174,"phases":1554,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":1555,"interventions":1556},[87],[479],[206,267,568],{"nctId":256,"briefTitle":257,"status":174,"phases":1558,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":1559,"interventions":1560},[87],[263,264,265],[248,267],{"trials":1562,"activeCount":192,"soonestReadout":1534},[1563,1567,1571,1579,1583],{"nctId":283,"briefTitle":284,"status":102,"phases":1564,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":1565,"interventions":1566},[88],[291],[293,294,248,295,296,267,297,298,278,299,170],{"nctId":745,"briefTitle":746,"status":174,"phases":1568,"primaryCompletion":415,"completion":415,"start":748,"enrollment":19,"conditions":1569,"interventions":1570},[88],[750],[267,752,155],{"nctId":1572,"briefTitle":1573,"status":344,"phases":1574,"start":1575,"enrollment":218,"conditions":1576,"interventions":1577},"NCT00162669","Bevacizumab in Advanced Hepatocellular Carcinoma",[88],"2005-05",[108],[1578],"bevacizumab",{"nctId":1531,"briefTitle":1532,"status":586,"phases":1580,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":188,"conditions":1581,"interventions":1582},[88],[1537],[1539,1540,752,151,267],{"nctId":1584,"briefTitle":1585,"status":114,"phases":1586,"primaryCompletion":1587,"completion":1587,"start":1588,"enrollment":901,"conditions":1589,"interventions":1590},"NCT05180006","Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy",[88],"2024-12-17","2022-02-24",[15],[319,267,1591,1592],"Pertuzumab","Trastuzumab",{"trials":1594,"activeCount":98},[],{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[],{"intervention":70,"totalTrials":27,"cells":1600},{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1609,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1602,"activeCount":98},[],{"trials":1604,"activeCount":98},[1605],{"nctId":269,"briefTitle":270,"status":114,"phases":1606,"primaryCompletion":272,"completion":273,"start":274,"enrollment":16,"conditions":1607,"interventions":1608},[87],[276],[70,278,248,279],{"trials":1610,"activeCount":192,"soonestReadout":59},[1611,1618,1633,1639],{"nctId":67,"briefTitle":68,"status":102,"phases":1612,"primaryCompletion":69,"completion":69,"start":1613,"enrollment":1614,"conditions":1615,"interventions":1617},[88],"2021-12-06",200,[1616],"Early Small (cT1N0) Triple Negative Breast Cancer",[70],{"nctId":1619,"briefTitle":1620,"status":127,"phases":1621,"primaryCompletion":1622,"completion":1623,"start":1624,"enrollment":98,"conditions":1625,"interventions":1631},"NCT03982173","Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors",[88],"2024-09","2024-12-05","2020-09",[1626,1627,1628,1629,1630],"Metastatic Colorectal Cancer","Triple Negative Breast Cancer","Prostate Adenocarcinoma","Stomach Adenocarcinoma","Esophageal Adenocarcinoma",[1632,70],"Tremelimumab",{"nctId":57,"briefTitle":58,"status":102,"phases":1634,"primaryCompletion":59,"completion":1635,"start":1636,"enrollment":218,"conditions":1637,"interventions":1638},[87,88],"2027-12-17","2024-07-05",[15],[60,70],{"nctId":1640,"briefTitle":1641,"status":174,"phases":1642,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":1645,"conditions":1646,"interventions":1648},"NCT03212469","A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer",[87,88],"2025-02-24","2017-06-20",54,[190,24,1647],"Oesophageal Cancer",[70,1632],{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":98},[],{"trials":1654,"activeCount":98},[],{"intervention":151,"totalTrials":27,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1693,"PHASE4":1695,"NA":1697},{"trials":1658,"activeCount":98},[],{"trials":1660,"activeCount":98},[],{"trials":1662,"activeCount":192,"soonestReadout":1534},[1663,1667,1671,1685,1689],{"nctId":813,"briefTitle":814,"status":114,"phases":1664,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":1665,"interventions":1666},[87,88],[820],[822,337,823,824,825,151],{"nctId":140,"briefTitle":141,"status":102,"phases":1668,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":1669,"interventions":1670},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"nctId":1672,"briefTitle":1673,"status":344,"phases":1674,"primaryCompletion":1675,"start":1676,"enrollment":1677,"conditions":1678,"interventions":1680},"NCT00811759","Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma",[87,88],"2009-05","2007-06",58,[1679],"Melanoma (Skin)",[1681,1682,1683,1684],"sorafenib tosylate","temozolomide","gene expression analysis","mutation analysis",{"nctId":1531,"briefTitle":1532,"status":586,"phases":1686,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":188,"conditions":1687,"interventions":1688},[88],[1537],[1539,1540,752,151,267],{"nctId":172,"briefTitle":173,"status":174,"phases":1690,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":1691,"interventions":1692},[87,88],[180],[50,151],{"trials":1694,"activeCount":98},[],{"trials":1696,"activeCount":98},[],{"trials":1698,"activeCount":98},[],{"intervention":170,"totalTrials":192,"cells":1700},{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1715,"PHASE4":1717,"NA":1719},{"trials":1702,"activeCount":98},[],{"trials":1704,"activeCount":98},[],{"trials":1706,"activeCount":192,"soonestReadout":286},[1707,1711],{"nctId":283,"briefTitle":284,"status":102,"phases":1708,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":1709,"interventions":1710},[88],[291],[293,294,248,295,296,267,297,298,278,299,170],{"nctId":140,"briefTitle":141,"status":102,"phases":1712,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":1713,"interventions":1714},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":1716,"activeCount":98},[],{"trials":1718,"activeCount":98},[],{"trials":1720,"activeCount":98},[],{"intervention":1512,"totalTrials":192,"cells":1722},{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1731,"PHASE3":1737,"PHASE4":1739,"NA":1741},{"trials":1724,"activeCount":98},[],{"trials":1726,"activeCount":136,"soonestReadout":1503},[1727],{"nctId":1500,"briefTitle":1501,"status":102,"phases":1728,"primaryCompletion":1503,"completion":589,"start":1504,"enrollment":1505,"conditions":1729,"interventions":1730},[87],[1507],[1509,752,1510,1511,1512],{"trials":1732,"activeCount":136,"soonestReadout":589},[1733],{"nctId":1520,"briefTitle":1521,"status":1100,"phases":1734,"primaryCompletion":589,"completion":1523,"start":1524,"enrollment":525,"conditions":1735,"interventions":1736},[88],[1526],[1528,752,1512,1529],{"trials":1738,"activeCount":98},[],{"trials":1740,"activeCount":98},[],{"trials":1742,"activeCount":98},[],{"intervention":298,"totalTrials":34,"cells":1744},{"EARLY_PHASE1":1745,"PHASE1":1747,"PHASE2":1761,"PHASE3":1778,"PHASE4":1784,"NA":1786},{"trials":1746,"activeCount":98},[],{"trials":1748,"activeCount":98},[1749],{"nctId":1750,"briefTitle":1751,"status":174,"phases":1752,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1758},"NCT02018874","A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine",[87],"2016-04","2013-09",52,[1757],"Solid Tumors and Non-Hodgkin's Lymphoma",[1759,1760],"LY2780301","Gemcitabine",{"trials":1762,"activeCount":136,"soonestReadout":286},[1763,1767],{"nctId":283,"briefTitle":284,"status":102,"phases":1764,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":1765,"interventions":1766},[88],[291],[293,294,248,295,296,267,297,298,278,299,170],{"nctId":1768,"briefTitle":1769,"status":174,"phases":1770,"enrollment":1771,"conditions":1772,"interventions":1777},"NCT00407433","Clinical Studies of Gemcitabine-Oxaliplatin",[88],156,[1773,1774,1775,1776],"Medulloblastoma","Central Nervous System Tumors","Neuroblastoma","Osteosarcoma",[1760],{"trials":1779,"activeCount":98},[1780],{"nctId":342,"briefTitle":343,"status":344,"phases":1781,"start":346,"enrollment":347,"conditions":1782,"interventions":1783},[89],[349],[351,298],{"trials":1785,"activeCount":98},[],{"trials":1787,"activeCount":98},[],{"intervention":163,"totalTrials":804,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1800,"PHASE4":1814,"NA":1816},{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[],{"trials":1795,"activeCount":136,"soonestReadout":143},[1796],{"nctId":140,"briefTitle":141,"status":102,"phases":1797,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":1798,"interventions":1799},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":1801,"activeCount":98},[1802,1810],{"nctId":1803,"briefTitle":1804,"status":174,"phases":1805,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":11,"conditions":1808,"interventions":1809},"NCT02672527","Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma",[89],"2018-07-14","2015-01-22",[1251],[867,163],{"nctId":708,"briefTitle":709,"status":174,"phases":1811,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":1812,"interventions":1813},[89],[716],[373,718,719,374,361,720,721,722,723,362],{"trials":1815,"activeCount":98},[],{"trials":1817,"activeCount":98},[],{"intervention":373,"totalTrials":804,"cells":1819},{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1830,"PHASE4":1840,"NA":1842},{"trials":1821,"activeCount":98},[],{"trials":1823,"activeCount":98},[],{"trials":1825,"activeCount":136,"soonestReadout":143},[1826],{"nctId":140,"briefTitle":141,"status":102,"phases":1827,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":1828,"interventions":1829},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":1831,"activeCount":98},[1832,1836],{"nctId":708,"briefTitle":709,"status":174,"phases":1833,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":1834,"interventions":1835},[89],[716],[373,718,719,374,361,720,721,722,723,362],{"nctId":366,"briefTitle":367,"status":344,"phases":1837,"start":369,"enrollment":370,"conditions":1838,"interventions":1839},[89],[24],[351,373,374,361],{"trials":1841,"activeCount":98},[],{"trials":1843,"activeCount":98},[],{"intervention":718,"totalTrials":192,"cells":1845},{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1856,"PHASE4":1862,"NA":1864},{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[],{"trials":1851,"activeCount":136,"soonestReadout":143},[1852],{"nctId":140,"briefTitle":141,"status":102,"phases":1853,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":1854,"interventions":1855},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":1857,"activeCount":98},[1858],{"nctId":708,"briefTitle":709,"status":174,"phases":1859,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":1860,"interventions":1861},[89],[716],[373,718,719,374,361,720,721,722,723,362],{"trials":1863,"activeCount":98},[],{"trials":1865,"activeCount":98},[],{"intervention":1539,"totalTrials":192,"cells":1867},{"EARLY_PHASE1":1868,"PHASE1":1870,"PHASE2":1872,"PHASE3":1878,"PHASE4":1892,"NA":1894},{"trials":1869,"activeCount":98},[],{"trials":1871,"activeCount":98},[],{"trials":1873,"activeCount":136,"soonestReadout":1534},[1874],{"nctId":1531,"briefTitle":1532,"status":586,"phases":1875,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":188,"conditions":1876,"interventions":1877},[88],[1537],[1539,1540,752,151,267],{"trials":1879,"activeCount":98},[1880],{"nctId":1881,"briefTitle":1882,"status":174,"phases":1883,"primaryCompletion":1884,"completion":1884,"start":1885,"enrollment":1886,"conditions":1887,"interventions":1888},"NCT02494973","Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases",[88,89],"2024-03-18","2015-05-26",104,[26],[1889,1890,1891,1539],"Oxaliplatin HAI","Oxaliplatin IV","mFOLFOX6",{"trials":1893,"activeCount":98},[],{"trials":1895,"activeCount":98},[],{"intervention":278,"totalTrials":804,"cells":1897},{"EARLY_PHASE1":1898,"PHASE1":1900,"PHASE2":1906,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1899,"activeCount":98},[],{"trials":1901,"activeCount":98},[1902],{"nctId":269,"briefTitle":270,"status":114,"phases":1903,"primaryCompletion":272,"completion":273,"start":274,"enrollment":16,"conditions":1904,"interventions":1905},[87],[276],[70,278,248,279],{"trials":1907,"activeCount":136,"soonestReadout":286},[1908,1912],{"nctId":283,"briefTitle":284,"status":102,"phases":1909,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":1910,"interventions":1911},[88],[291],[293,294,248,295,296,267,297,298,278,299,170],{"nctId":1913,"briefTitle":1914,"status":1915,"phases":1916,"start":1917,"enrollment":1918,"conditions":1919,"interventions":1920},"NCT00127088","Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients","SUSPENDED",[88],"2004-10",37,[21],[1921],"docetaxel",{"trials":1923,"activeCount":98},[],{"trials":1925,"activeCount":98},[],{"trials":1927,"activeCount":98},[],{"intervention":150,"totalTrials":192,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1934,"PHASE3":1944,"PHASE4":1946,"NA":1948},{"trials":1931,"activeCount":98},[],{"trials":1933,"activeCount":98},[],{"trials":1935,"activeCount":136,"soonestReadout":143},[1936,1940],{"nctId":140,"briefTitle":141,"status":102,"phases":1937,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":1938,"interventions":1939},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"nctId":827,"briefTitle":828,"status":114,"phases":1941,"primaryCompletion":830,"completion":831,"start":832,"enrollment":833,"conditions":1942,"interventions":1943},[88],[835],[150,337],{"trials":1945,"activeCount":98},[],{"trials":1947,"activeCount":98},[],{"trials":1949,"activeCount":98},[],{"intervention":1951,"totalTrials":136,"cells":1952},"Elacestrant",{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1957,"PHASE3":1969,"PHASE4":1971,"NA":1973},{"trials":1954,"activeCount":98},[],{"trials":1956,"activeCount":98},[],{"trials":1958,"activeCount":136,"soonestReadout":1963},[1959],{"nctId":1960,"briefTitle":1961,"status":102,"phases":1962,"primaryCompletion":1963,"completion":1964,"start":1965,"enrollment":188,"conditions":1966,"interventions":1967},"NCT07159451","A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+\u002FHER2- Breast Cancer",[88],"2027-01-29","2027-05-29","2025-10-06",[15],[1951,1968],"Leuprorelin",{"trials":1970,"activeCount":98},[],{"trials":1972,"activeCount":98},[],{"trials":1974,"activeCount":98},[],{"intervention":1968,"totalTrials":136,"cells":1976},{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1987,"PHASE4":1989,"NA":1991},{"trials":1978,"activeCount":98},[],{"trials":1980,"activeCount":98},[],{"trials":1982,"activeCount":136,"soonestReadout":1963},[1983],{"nctId":1960,"briefTitle":1961,"status":102,"phases":1984,"primaryCompletion":1963,"completion":1964,"start":1965,"enrollment":188,"conditions":1985,"interventions":1986},[88],[15],[1951,1968],{"trials":1988,"activeCount":98},[],{"trials":1990,"activeCount":98},[],{"trials":1992,"activeCount":98},[],{"intervention":456,"totalTrials":136,"cells":1994},{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":1996,"activeCount":98},[],{"trials":1998,"activeCount":98},[],{"trials":2000,"activeCount":136,"soonestReadout":446},[2001],{"nctId":443,"briefTitle":444,"status":102,"phases":2002,"primaryCompletion":446,"completion":447,"start":448,"enrollment":449,"conditions":2003,"interventions":2004},[87,88],[451,452,453,454],[456,154],{"trials":2006,"activeCount":98},[],{"trials":2008,"activeCount":98},[],{"trials":2010,"activeCount":98},[],{"intervention":293,"totalTrials":136,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2014,"activeCount":98},[],{"trials":2016,"activeCount":98},[],{"trials":2018,"activeCount":136,"soonestReadout":286},[2019],{"nctId":283,"briefTitle":284,"status":102,"phases":2020,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":2021,"interventions":2022},[88],[291],[293,294,248,295,296,267,297,298,278,299,170],{"trials":2024,"activeCount":98},[],{"trials":2026,"activeCount":98},[],{"trials":2028,"activeCount":98},[],{"intervention":294,"totalTrials":136,"cells":2030},{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2035,"PHASE3":2041,"PHASE4":2043,"NA":2045},{"trials":2032,"activeCount":98},[],{"trials":2034,"activeCount":98},[],{"trials":2036,"activeCount":136,"soonestReadout":286},[2037],{"nctId":283,"briefTitle":284,"status":102,"phases":2038,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":2039,"interventions":2040},[88],[291],[293,294,248,295,296,267,297,298,278,299,170],{"trials":2042,"activeCount":98},[],{"trials":2044,"activeCount":98},[],{"trials":2046,"activeCount":98},[],{"intervention":295,"totalTrials":136,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2059,"PHASE4":2061,"NA":2063},{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[],{"trials":2054,"activeCount":136,"soonestReadout":286},[2055],{"nctId":283,"briefTitle":284,"status":102,"phases":2056,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":2057,"interventions":2058},[88],[291],[293,294,248,295,296,267,297,298,278,299,170],{"trials":2060,"activeCount":98},[],{"trials":2062,"activeCount":98},[],{"trials":2064,"activeCount":98},[],{"intervention":296,"totalTrials":136,"cells":2066},{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2077,"PHASE4":2079,"NA":2081},{"trials":2068,"activeCount":98},[],{"trials":2070,"activeCount":98},[],{"trials":2072,"activeCount":136,"soonestReadout":286},[2073],{"nctId":283,"briefTitle":284,"status":102,"phases":2074,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":2075,"interventions":2076},[88],[291],[293,294,248,295,296,267,297,298,278,299,170],{"trials":2078,"activeCount":98},[],{"trials":2080,"activeCount":98},[],{"trials":2082,"activeCount":98},[],{"intervention":297,"totalTrials":136,"cells":2084},{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2095,"PHASE4":2097,"NA":2099},{"trials":2086,"activeCount":98},[],{"trials":2088,"activeCount":98},[],{"trials":2090,"activeCount":136,"soonestReadout":286},[2091],{"nctId":283,"briefTitle":284,"status":102,"phases":2092,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":2093,"interventions":2094},[88],[291],[293,294,248,295,296,267,297,298,278,299,170],{"trials":2096,"activeCount":98},[],{"trials":2098,"activeCount":98},[],{"trials":2100,"activeCount":98},[],{"intervention":299,"totalTrials":136,"cells":2102},{"EARLY_PHASE1":2103,"PHASE1":2105,"PHASE2":2107,"PHASE3":2113,"PHASE4":2115,"NA":2117},{"trials":2104,"activeCount":98},[],{"trials":2106,"activeCount":98},[],{"trials":2108,"activeCount":136,"soonestReadout":286},[2109],{"nctId":283,"briefTitle":284,"status":102,"phases":2110,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":2111,"interventions":2112},[88],[291],[293,294,248,295,296,267,297,298,278,299,170],{"trials":2114,"activeCount":98},[],{"trials":2116,"activeCount":98},[],{"trials":2118,"activeCount":98},[],{"intervention":149,"totalTrials":136,"cells":2120},{"EARLY_PHASE1":2121,"PHASE1":2123,"PHASE2":2125,"PHASE3":2131,"PHASE4":2133,"NA":2135},{"trials":2122,"activeCount":98},[],{"trials":2124,"activeCount":98},[],{"trials":2126,"activeCount":136,"soonestReadout":143},[2127],{"nctId":140,"briefTitle":141,"status":102,"phases":2128,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2129,"interventions":2130},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2132,"activeCount":98},[],{"trials":2134,"activeCount":98},[],{"trials":2136,"activeCount":98},[],{"intervention":153,"totalTrials":136,"cells":2138},{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2149,"PHASE4":2151,"NA":2153},{"trials":2140,"activeCount":98},[],{"trials":2142,"activeCount":98},[],{"trials":2144,"activeCount":136,"soonestReadout":143},[2145],{"nctId":140,"briefTitle":141,"status":102,"phases":2146,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2147,"interventions":2148},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2150,"activeCount":98},[],{"trials":2152,"activeCount":98},[],{"trials":2154,"activeCount":98},[],{"intervention":156,"totalTrials":136,"cells":2156},{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2158,"activeCount":98},[],{"trials":2160,"activeCount":98},[],{"trials":2162,"activeCount":136,"soonestReadout":143},[2163],{"nctId":140,"briefTitle":141,"status":102,"phases":2164,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2165,"interventions":2166},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2168,"activeCount":98},[],{"trials":2170,"activeCount":98},[],{"trials":2172,"activeCount":98},[],{"intervention":158,"totalTrials":136,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2176,"activeCount":98},[],{"trials":2178,"activeCount":98},[],{"trials":2180,"activeCount":136,"soonestReadout":143},[2181],{"nctId":140,"briefTitle":141,"status":102,"phases":2182,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2183,"interventions":2184},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2186,"activeCount":98},[],{"trials":2188,"activeCount":98},[],{"trials":2190,"activeCount":98},[],{"intervention":159,"totalTrials":136,"cells":2192},{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2203,"PHASE4":2205,"NA":2207},{"trials":2194,"activeCount":98},[],{"trials":2196,"activeCount":98},[],{"trials":2198,"activeCount":136,"soonestReadout":143},[2199],{"nctId":140,"briefTitle":141,"status":102,"phases":2200,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2201,"interventions":2202},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2204,"activeCount":98},[],{"trials":2206,"activeCount":98},[],{"trials":2208,"activeCount":98},[],{"intervention":160,"totalTrials":136,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2221,"PHASE4":2223,"NA":2225},{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":98},[],{"trials":2216,"activeCount":136,"soonestReadout":143},[2217],{"nctId":140,"briefTitle":141,"status":102,"phases":2218,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2219,"interventions":2220},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[],{"intervention":161,"totalTrials":136,"cells":2228},{"EARLY_PHASE1":2229,"PHASE1":2231,"PHASE2":2233,"PHASE3":2239,"PHASE4":2241,"NA":2243},{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":136,"soonestReadout":143},[2235],{"nctId":140,"briefTitle":141,"status":102,"phases":2236,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2237,"interventions":2238},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2240,"activeCount":98},[],{"trials":2242,"activeCount":98},[],{"trials":2244,"activeCount":98},[],{"intervention":164,"totalTrials":136,"cells":2246},{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2257,"PHASE4":2259,"NA":2261},{"trials":2248,"activeCount":98},[],{"trials":2250,"activeCount":98},[],{"trials":2252,"activeCount":136,"soonestReadout":143},[2253],{"nctId":140,"briefTitle":141,"status":102,"phases":2254,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2255,"interventions":2256},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":98},[],{"trials":2262,"activeCount":98},[],{"intervention":165,"totalTrials":136,"cells":2264},{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2266,"activeCount":98},[],{"trials":2268,"activeCount":98},[],{"trials":2270,"activeCount":136,"soonestReadout":143},[2271],{"nctId":140,"briefTitle":141,"status":102,"phases":2272,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2273,"interventions":2274},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2276,"activeCount":98},[],{"trials":2278,"activeCount":98},[],{"trials":2280,"activeCount":98},[],{"intervention":166,"totalTrials":136,"cells":2282},{"EARLY_PHASE1":2283,"PHASE1":2285,"PHASE2":2287,"PHASE3":2293,"PHASE4":2295,"NA":2297},{"trials":2284,"activeCount":98},[],{"trials":2286,"activeCount":98},[],{"trials":2288,"activeCount":136,"soonestReadout":143},[2289],{"nctId":140,"briefTitle":141,"status":102,"phases":2290,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2291,"interventions":2292},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2294,"activeCount":98},[],{"trials":2296,"activeCount":98},[],{"trials":2298,"activeCount":98},[],{"intervention":167,"totalTrials":136,"cells":2300},{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2311,"PHASE4":2313,"NA":2315},{"trials":2302,"activeCount":98},[],{"trials":2304,"activeCount":98},[],{"trials":2306,"activeCount":136,"soonestReadout":143},[2307],{"nctId":140,"briefTitle":141,"status":102,"phases":2308,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2309,"interventions":2310},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2312,"activeCount":98},[],{"trials":2314,"activeCount":98},[],{"trials":2316,"activeCount":98},[],{"intervention":168,"totalTrials":136,"cells":2318},{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2323,"PHASE3":2329,"PHASE4":2331,"NA":2333},{"trials":2320,"activeCount":98},[],{"trials":2322,"activeCount":98},[],{"trials":2324,"activeCount":136,"soonestReadout":143},[2325],{"nctId":140,"briefTitle":141,"status":102,"phases":2326,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2327,"interventions":2328},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2330,"activeCount":98},[],{"trials":2332,"activeCount":98},[],{"trials":2334,"activeCount":98},[],{"intervention":169,"totalTrials":136,"cells":2336},{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2347,"PHASE4":2349,"NA":2351},{"trials":2338,"activeCount":98},[],{"trials":2340,"activeCount":98},[],{"trials":2342,"activeCount":136,"soonestReadout":143},[2343],{"nctId":140,"briefTitle":141,"status":102,"phases":2344,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":2345,"interventions":2346},[87,88],[147],[149,150,151,152,153,40,154,155,156,50,157,158,159,160,161,162,163,164,165,166,167,168,169,170],{"trials":2348,"activeCount":98},[],{"trials":2350,"activeCount":98},[],{"trials":2352,"activeCount":98},[],{"intervention":2354,"totalTrials":136,"cells":2355},"ASP3082",{"EARLY_PHASE1":2356,"PHASE1":2358,"PHASE2":2360,"PHASE3":2372,"PHASE4":2374,"NA":2376},{"trials":2357,"activeCount":98},[],{"trials":2359,"activeCount":98},[],{"trials":2361,"activeCount":136,"soonestReadout":446},[2362],{"nctId":2363,"briefTitle":2364,"status":102,"phases":2365,"primaryCompletion":446,"completion":2366,"start":2367,"enrollment":591,"conditions":2368,"interventions":2371},"NCT07483983","Study Investigating ASP3082 in Patients With Metastatic\u002FLocally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response\u002FResistance",[88],"2027-10","2026-03",[2369,2370],"Metastatic\u002FLocally Advanced Non-Small-Cell Lung Cancer","Metastatic\u002FLocally Pancreatic Ductal Adenocarcinoma",[2354],{"trials":2373,"activeCount":98},[],{"trials":2375,"activeCount":98},[],{"trials":2377,"activeCount":98},[],{"intervention":65,"totalTrials":136,"cells":2379},{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2395,"PHASE4":2397,"NA":2399},{"trials":2381,"activeCount":98},[],{"trials":2383,"activeCount":98},[],{"trials":2385,"activeCount":136,"soonestReadout":64},[2386],{"nctId":62,"briefTitle":63,"status":586,"phases":2387,"primaryCompletion":64,"completion":2388,"start":2389,"enrollment":2390,"conditions":2391,"interventions":2393},[88],"2027-04","2019-01-02",45,[2392],"Relapsing\u002FRefractory ALK+ Anaplastic Large Cell Lymphoma",[65,2394],"Nivolumab cohort 2",{"trials":2396,"activeCount":98},[],{"trials":2398,"activeCount":98},[],{"trials":2400,"activeCount":98},[],{"intervention":2394,"totalTrials":136,"cells":2402},{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2407,"PHASE3":2413,"PHASE4":2415,"NA":2417},{"trials":2404,"activeCount":98},[],{"trials":2406,"activeCount":98},[],{"trials":2408,"activeCount":136,"soonestReadout":64},[2409],{"nctId":62,"briefTitle":63,"status":586,"phases":2410,"primaryCompletion":64,"completion":2388,"start":2389,"enrollment":2390,"conditions":2411,"interventions":2412},[88],[2392],[65,2394],{"trials":2414,"activeCount":98},[],{"trials":2416,"activeCount":98},[],{"trials":2418,"activeCount":98},[],{"intervention":2420,"totalTrials":136,"cells":2421},"Sotorasib 120Mg Tab",{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2438,"PHASE4":2440,"NA":2442},{"trials":2423,"activeCount":98},[],{"trials":2425,"activeCount":98},[],{"trials":2427,"activeCount":136,"soonestReadout":2432},[2428],{"nctId":2429,"briefTitle":2430,"status":102,"phases":2431,"primaryCompletion":2432,"completion":2432,"start":2433,"enrollment":2434,"conditions":2435,"interventions":2437},"NCT05631249","Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C",[88],"2027-12-12","2022-12-13",40,[2436,31],"KRAS P.G12C",[2420],{"trials":2439,"activeCount":98},[],{"trials":2441,"activeCount":98},[],{"trials":2443,"activeCount":98},[],{"intervention":2445,"totalTrials":136,"cells":2446},"Valemetostat Tosylate",{"EARLY_PHASE1":2447,"PHASE1":2449,"PHASE2":2451,"PHASE3":2465,"PHASE4":2467,"NA":2469},{"trials":2448,"activeCount":98},[],{"trials":2450,"activeCount":98},[],{"trials":2452,"activeCount":136,"soonestReadout":2457},[2453],{"nctId":2454,"briefTitle":2455,"status":102,"phases":2456,"primaryCompletion":2457,"completion":2458,"start":2459,"enrollment":2460,"conditions":2461,"interventions":2464},"NCT07303387","Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.",[88],"2031-02-28","2032-02-28","2026-03-05",900,[2462,2463,479],"Solid Tumor Malignancies","Clear Cell Endometrial Carcinoma",[2445],{"trials":2466,"activeCount":98},[],{"trials":2468,"activeCount":98},[],{"trials":2470,"activeCount":98},[],{"intervention":75,"totalTrials":136,"cells":2472},{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2477,"PHASE3":2486,"PHASE4":2488,"NA":2490},{"trials":2474,"activeCount":98},[],{"trials":2476,"activeCount":98},[],{"trials":2478,"activeCount":136,"soonestReadout":74},[2479],{"nctId":72,"briefTitle":73,"status":102,"phases":2480,"primaryCompletion":74,"completion":588,"start":2481,"enrollment":1677,"conditions":2482,"interventions":2485},[87,88],"2024-07-11",[2483,2484],"Oligometastatic Disease","Solid Tumor, Adult",[75],{"trials":2487,"activeCount":98},[],{"trials":2489,"activeCount":98},[],{"trials":2491,"activeCount":98},[],{"intervention":1528,"totalTrials":136,"cells":2493},{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2504,"PHASE4":2506,"NA":2508},{"trials":2495,"activeCount":98},[],{"trials":2497,"activeCount":98},[],{"trials":2499,"activeCount":136,"soonestReadout":589},[2500],{"nctId":1520,"briefTitle":1521,"status":1100,"phases":2501,"primaryCompletion":589,"completion":1523,"start":1524,"enrollment":525,"conditions":2502,"interventions":2503},[88],[1526],[1528,752,1512,1529],{"trials":2505,"activeCount":98},[],{"trials":2507,"activeCount":98},[],{"trials":2509,"activeCount":98},[],{"intervention":1529,"totalTrials":136,"cells":2511},{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2522,"PHASE4":2524,"NA":2526},{"trials":2513,"activeCount":98},[],{"trials":2515,"activeCount":98},[],{"trials":2517,"activeCount":136,"soonestReadout":589},[2518],{"nctId":1520,"briefTitle":1521,"status":1100,"phases":2519,"primaryCompletion":589,"completion":1523,"start":1524,"enrollment":525,"conditions":2520,"interventions":2521},[88],[1526],[1528,752,1512,1529],{"trials":2523,"activeCount":98},[],{"trials":2525,"activeCount":98},[],{"trials":2527,"activeCount":98},[],{"intervention":1540,"totalTrials":136,"cells":2529},{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2534,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2531,"activeCount":98},[],{"trials":2533,"activeCount":98},[],{"trials":2535,"activeCount":136,"soonestReadout":1534},[2536],{"nctId":1531,"briefTitle":1532,"status":586,"phases":2537,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":188,"conditions":2538,"interventions":2539},[88],[1537],[1539,1540,752,151,267],{"trials":2541,"activeCount":98},[],{"trials":2543,"activeCount":98},[],{"trials":2545,"activeCount":98},[],{"intervention":60,"totalTrials":136,"cells":2547},{"EARLY_PHASE1":2548,"PHASE1":2550,"PHASE2":2552,"PHASE3":2558,"PHASE4":2560,"NA":2562},{"trials":2549,"activeCount":98},[],{"trials":2551,"activeCount":98},[],{"trials":2553,"activeCount":136,"soonestReadout":59},[2554],{"nctId":57,"briefTitle":58,"status":102,"phases":2555,"primaryCompletion":59,"completion":1635,"start":1636,"enrollment":218,"conditions":2556,"interventions":2557},[87,88],[15],[60,70],{"trials":2559,"activeCount":98},[],{"trials":2561,"activeCount":98},[],{"trials":2563,"activeCount":98},[],{"intervention":55,"totalTrials":136,"cells":2565},{"EARLY_PHASE1":2566,"PHASE1":2568,"PHASE2":2570,"PHASE3":2581,"PHASE4":2583,"NA":2585},{"trials":2567,"activeCount":98},[],{"trials":2569,"activeCount":98},[],{"trials":2571,"activeCount":136,"soonestReadout":54},[2572],{"nctId":52,"briefTitle":53,"status":102,"phases":2573,"primaryCompletion":54,"completion":2574,"start":2575,"enrollment":525,"conditions":2576,"interventions":2579},[87,88],"2026-08","2023-07-31",[2577,2578],"Head and Neck Carcinoma","Adult Disease",[55,2580],"HPVDC injection level dose 2",{"trials":2582,"activeCount":98},[],{"trials":2584,"activeCount":98},[],{"trials":2586,"activeCount":98},[],{"intervention":2580,"totalTrials":136,"cells":2588},{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2599,"PHASE4":2601,"NA":2603},{"trials":2590,"activeCount":98},[],{"trials":2592,"activeCount":98},[],{"trials":2594,"activeCount":136,"soonestReadout":54},[2595],{"nctId":52,"briefTitle":53,"status":102,"phases":2596,"primaryCompletion":54,"completion":2574,"start":2575,"enrollment":525,"conditions":2597,"interventions":2598},[87,88],[2577,2578],[55,2580],{"trials":2600,"activeCount":98},[],{"trials":2602,"activeCount":98},[],{"trials":2604,"activeCount":98},[],{"intervention":2606,"totalTrials":136,"cells":2607},"U3-1402",{"EARLY_PHASE1":2608,"PHASE1":2610,"PHASE2":2612,"PHASE3":2625,"PHASE4":2627,"NA":2629},{"trials":2609,"activeCount":98},[],{"trials":2611,"activeCount":98},[],{"trials":2613,"activeCount":136,"soonestReadout":2618},[2614],{"nctId":2615,"briefTitle":2616,"status":102,"phases":2617,"primaryCompletion":2618,"completion":2619,"start":2620,"enrollment":2621,"conditions":2622,"interventions":2624},"NCT04965766","Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer",[88],"2027-04-11","2030-04-11","2021-05-11",139,[2623,454],"Metastatic Breast Cancer",[2606],{"trials":2626,"activeCount":98},[],{"trials":2628,"activeCount":98},[],{"trials":2630,"activeCount":98},[],{"intervention":2632,"totalTrials":136,"cells":2633},"DS-1062a",{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2638,"PHASE3":2651,"PHASE4":2653,"NA":2655},{"trials":2635,"activeCount":98},[],{"trials":2637,"activeCount":98},[],{"trials":2639,"activeCount":136,"soonestReadout":216},[2640],{"nctId":2641,"briefTitle":2642,"status":586,"phases":2643,"primaryCompletion":216,"completion":676,"start":2644,"enrollment":2645,"conditions":2646,"interventions":2650},"NCT04940325","Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and\u002For Unresectable Non-Small Cell Lung Cancer",[88],"2021-05-12",100,[2647,2648,2649],"Metastatic Lung Cancer","Advanced Non Small Cell Lung Cancer","Unresectable Non-small Lung Cancer",[2632],{"trials":2652,"activeCount":98},[],{"trials":2654,"activeCount":98},[],{"trials":2656,"activeCount":98},[],{"intervention":2658,"totalTrials":136,"cells":2659},"Tarlatamab",{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2678,"PHASE4":2680,"NA":2682},{"trials":2661,"activeCount":98},[],{"trials":2663,"activeCount":98},[],{"trials":2665,"activeCount":136,"soonestReadout":2670},[2666],{"nctId":2667,"briefTitle":2668,"status":102,"phases":2669,"primaryCompletion":2670,"completion":2671,"start":2672,"enrollment":2434,"conditions":2673,"interventions":2677},"NCT07016230","Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic\u002FLocally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response\u002FResistance (UNLOCK TARLATAMAB)",[88],"2027-04-15","2030-01-15","2025-07-02",[2674,2675,2676],"Metastatic\u002FLocally Advanced Small-Cell Lung Cancer","Metastatic\u002FLocally Advanced Poorly Differentiated NEC","Metastatic\u002FLocally Advanced High-grade MTC",[2658],{"trials":2679,"activeCount":98},[],{"trials":2681,"activeCount":98},[],{"trials":2683,"activeCount":98},[],{"intervention":2685,"totalTrials":192,"cells":2686},"Indocyanine Green",{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2699,"PHASE4":2701,"NA":2703},{"trials":2688,"activeCount":98},[],{"trials":2690,"activeCount":98},[],{"trials":2692,"activeCount":136,"soonestReadout":79},[2693],{"nctId":82,"briefTitle":83,"status":102,"phases":2694,"primaryCompletion":79,"completion":79,"start":2695,"enrollment":2696,"conditions":2697,"interventions":2698},[88],"2020-12-15",65,[33],[84],{"trials":2700,"activeCount":98},[],{"trials":2702,"activeCount":98},[],{"trials":2704,"activeCount":98},[2705],{"nctId":2706,"briefTitle":2707,"status":174,"phases":2708,"primaryCompletion":2709,"completion":2710,"start":2711,"enrollment":2712,"conditions":2713,"interventions":2714},"NCT02994225","Axillary Reverse Mapping Using Near-infrared Imaging in Invasive Breast Cancer: Predictors of Nodal Positivity",[91],"2019-06-07","2019-08-05","2017-03-10",120,[15],[2685],{"intervention":2716,"totalTrials":136,"cells":2717},"anti-CD19 CAR-T cells",{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2736,"PHASE3":2738,"PHASE4":2740,"NA":2742},{"trials":2719,"activeCount":98},[],{"trials":2721,"activeCount":136,"soonestReadout":2726},[2722],{"nctId":2723,"briefTitle":2724,"status":1100,"phases":2725,"primaryCompletion":2726,"completion":2727,"start":2728,"enrollment":22,"conditions":2729,"interventions":2735},"NCT07544225","Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases",[87],"2029-02-01","2043-02-01","2026-09-01",[2730,2731,2732,2733,2734],"Rheumatoid Arthritis (RA)","Systemic Lupus Erythematosus (SLE)","Sjogren's Disease With Dry Eyes","Systemic Sclerosis (SSc)","Idiopathic Inflammatory Myositis (IIM)",[2716],{"trials":2737,"activeCount":98},[],{"trials":2739,"activeCount":98},[],{"trials":2741,"activeCount":98},[],{"trials":2743,"activeCount":98},[],{"intervention":1509,"totalTrials":136,"cells":2745},{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2754,"PHASE3":2756,"PHASE4":2758,"NA":2760},{"trials":2747,"activeCount":98},[],{"trials":2749,"activeCount":136,"soonestReadout":1503},[2750],{"nctId":1500,"briefTitle":1501,"status":102,"phases":2751,"primaryCompletion":1503,"completion":589,"start":1504,"enrollment":1505,"conditions":2752,"interventions":2753},[87],[1507],[1509,752,1510,1511,1512],{"trials":2755,"activeCount":98},[],{"trials":2757,"activeCount":98},[],{"trials":2759,"activeCount":98},[],{"trials":2761,"activeCount":98},[],{"intervention":1510,"totalTrials":136,"cells":2763},{"EARLY_PHASE1":2764,"PHASE1":2766,"PHASE2":2772,"PHASE3":2774,"PHASE4":2776,"NA":2778},{"trials":2765,"activeCount":98},[],{"trials":2767,"activeCount":136,"soonestReadout":1503},[2768],{"nctId":1500,"briefTitle":1501,"status":102,"phases":2769,"primaryCompletion":1503,"completion":589,"start":1504,"enrollment":1505,"conditions":2770,"interventions":2771},[87],[1507],[1509,752,1510,1511,1512],{"trials":2773,"activeCount":98},[],{"trials":2775,"activeCount":98},[],{"trials":2777,"activeCount":98},[],{"trials":2779,"activeCount":98},[],{"intervention":1511,"totalTrials":136,"cells":2781},{"EARLY_PHASE1":2782,"PHASE1":2784,"PHASE2":2790,"PHASE3":2792,"PHASE4":2794,"NA":2796},{"trials":2783,"activeCount":98},[],{"trials":2785,"activeCount":136,"soonestReadout":1503},[2786],{"nctId":1500,"briefTitle":1501,"status":102,"phases":2787,"primaryCompletion":1503,"completion":589,"start":1504,"enrollment":1505,"conditions":2788,"interventions":2789},[87],[1507],[1509,752,1510,1511,1512],{"trials":2791,"activeCount":98},[],{"trials":2793,"activeCount":98},[],{"trials":2795,"activeCount":98},[],{"trials":2797,"activeCount":98},[],{"intervention":2799,"totalTrials":136,"cells":2800},"regorafenib",{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2814,"PHASE3":2816,"PHASE4":2818,"NA":2820},{"trials":2802,"activeCount":98},[],{"trials":2804,"activeCount":136,"soonestReadout":2388},[2805],{"nctId":2806,"briefTitle":2807,"status":586,"phases":2808,"primaryCompletion":2388,"completion":2366,"start":2809,"enrollment":2810,"conditions":2811,"interventions":2813},"NCT05830084","Phase Ib \u002F Regorafenib With Conventional Chemotherapy\u002FNewly Diagnosed Patients\u002F Multimetastatic Ewing Sarcoma",[87],"2023-06-16",23,[2812],"Ewing Sarcoma",[2799],{"trials":2815,"activeCount":98},[],{"trials":2817,"activeCount":98},[],{"trials":2819,"activeCount":98},[],{"trials":2821,"activeCount":98},[],{"intervention":2823,"totalTrials":136,"cells":2824},"BEP Protocol",{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2829,"PHASE3":2831,"PHASE4":2833,"NA":2835},{"trials":2826,"activeCount":98},[],{"trials":2828,"activeCount":98},[],{"trials":2830,"activeCount":98},[],{"trials":2832,"activeCount":98},[],{"trials":2834,"activeCount":98},[],{"trials":2836,"activeCount":136,"soonestReadout":143},[2837],{"nctId":2838,"briefTitle":2839,"status":102,"phases":2840,"primaryCompletion":143,"completion":2841,"start":2842,"enrollment":880,"conditions":2843,"interventions":2845},"NCT05705687","Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors",[91],"2037-02","2023-05-05",[2844],"Non-Seminomatous Germ Cell Tumor",[2823,2846],"Dose-dense regimen",{"intervention":2846,"totalTrials":136,"cells":2848},{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2855,"PHASE4":2857,"NA":2859},{"trials":2850,"activeCount":98},[],{"trials":2852,"activeCount":98},[],{"trials":2854,"activeCount":98},[],{"trials":2856,"activeCount":98},[],{"trials":2858,"activeCount":98},[],{"trials":2860,"activeCount":136,"soonestReadout":143},[2861],{"nctId":2838,"briefTitle":2839,"status":102,"phases":2862,"primaryCompletion":143,"completion":2841,"start":2842,"enrollment":880,"conditions":2863,"interventions":2864},[91],[2844],[2823,2846],{"intervention":2866,"totalTrials":136,"cells":2867},"Solid tumor and CT DNA",{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2874,"PHASE4":2876,"NA":2878},{"trials":2869,"activeCount":98},[],{"trials":2871,"activeCount":98},[],{"trials":2873,"activeCount":98},[],{"trials":2875,"activeCount":98},[],{"trials":2877,"activeCount":98},[],{"trials":2879,"activeCount":136,"soonestReadout":2884},[2880],{"nctId":2881,"briefTitle":2882,"status":102,"phases":2883,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":2886,"conditions":2887,"interventions":2889},"NCT05691608","MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2",[91],"2030-09-09","2022-09-09",1800,[2888,1161],"Solid Tumor",[2866],{"intervention":2891,"totalTrials":136,"cells":2892},"Blood sample",{"EARLY_PHASE1":2893,"PHASE1":2895,"PHASE2":2897,"PHASE3":2899,"PHASE4":2901,"NA":2903},{"trials":2894,"activeCount":98},[],{"trials":2896,"activeCount":98},[],{"trials":2898,"activeCount":98},[],{"trials":2900,"activeCount":98},[],{"trials":2902,"activeCount":98},[],{"trials":2904,"activeCount":136,"soonestReadout":2909},[2905],{"nctId":2906,"briefTitle":2907,"status":102,"phases":2908,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":2912,"interventions":2916},"NCT05890781","Engineering Immune Organoids to Study Pediatric Cancer",[91],"2028-05","2023-05-12",108,[2913,2914,1775,2915],"Brain Tumor","Kidney Tumor","Sarcoma",[2891],{"intervention":2918,"totalTrials":136,"cells":2919},"Sampling",{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2924,"PHASE3":2926,"PHASE4":2928,"NA":2930},{"trials":2921,"activeCount":98},[],{"trials":2923,"activeCount":98},[],{"trials":2925,"activeCount":98},[],{"trials":2927,"activeCount":98},[],{"trials":2929,"activeCount":98},[],{"trials":2931,"activeCount":136,"soonestReadout":2936},[2932],{"nctId":2933,"briefTitle":2934,"status":102,"phases":2935,"primaryCompletion":2936,"completion":2936,"start":2937,"enrollment":2938,"conditions":2939,"interventions":2941},"NCT07512882","Cohort of Patients With Chronic Myelomonocytic Leukemia",[],"2040-03","2026-05-05",5000,[1161,2940],"Myelomonocytic Leukemia, Chronic",[2918],{"intervention":2943,"totalTrials":136,"cells":2944},"blood sampling",{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2949,"PHASE3":2951,"PHASE4":2953,"NA":2955},{"trials":2946,"activeCount":98},[],{"trials":2948,"activeCount":98},[],{"trials":2950,"activeCount":98},[],{"trials":2952,"activeCount":98},[],{"trials":2954,"activeCount":98},[],{"trials":2956,"activeCount":136,"soonestReadout":2961},[2957],{"nctId":2958,"briefTitle":2959,"status":102,"phases":2960,"primaryCompletion":2961,"completion":2962,"start":2963,"enrollment":218,"conditions":2964,"interventions":2967},"NCT06813573","Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma",[91],"2028-10","2029-10","2024-09-30",[2965,2966],"Follicular Lymphoma","Diffuse Large B-Cell Lymphoma",[2943],{"intervention":2969,"totalTrials":136,"cells":2970},"biopsy liquid",{"EARLY_PHASE1":2971,"PHASE1":2973,"PHASE2":2975,"PHASE3":2977,"PHASE4":2979,"NA":2981},{"trials":2972,"activeCount":98},[],{"trials":2974,"activeCount":98},[],{"trials":2976,"activeCount":98},[],{"trials":2978,"activeCount":98},[],{"trials":2980,"activeCount":98},[],{"trials":2982,"activeCount":136,"soonestReadout":2987},[2983],{"nctId":2984,"briefTitle":2985,"status":102,"phases":2986,"primaryCompletion":2987,"completion":2988,"start":2989,"enrollment":2990,"conditions":2991,"interventions":2992},"NCT05283044","Implementing Precision Medicine in cOmmunity HospiTALs",[91],"2028-11-15","2030-04-15","2022-06-29",10000,[29],[2969],{"intervention":2994,"totalTrials":34,"cells":2995},"Chemotherapy",{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3012,"PHASE3":3036,"PHASE4":3048,"NA":3050},{"trials":2997,"activeCount":98},[],{"trials":2999,"activeCount":98},[3000],{"nctId":3001,"briefTitle":3002,"status":344,"phases":3003,"primaryCompletion":3004,"completion":3005,"start":3006,"enrollment":3007,"conditions":3008,"interventions":3010},"NCT03308604","AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy",[87],"2022-07","2024-05","2018-05-17",18,[3009],"Gynecologic Cancer",[3011,2994],"Polysiloxane Gd-Chelates based nanoparticles",{"trials":3013,"activeCount":98},[3014,3024],{"nctId":3015,"briefTitle":3016,"status":174,"phases":3017,"primaryCompletion":3018,"completion":3018,"start":3019,"enrollment":3020,"conditions":3021,"interventions":3023},"NCT00936156","Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years",[88],"2012-01","2009-01",68,[3022],"Metastatic, Cerebral Primitive Neuroectodermal Tumors",[2994],{"nctId":3025,"briefTitle":3026,"status":344,"phases":3027,"start":3028,"conditions":3029,"interventions":3032},"NCT00006112","Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer",[88],"1996-01",[3030,26,3031],"Carcinoma of the Appendix","Primary Peritoneal Cavity Cancer",[3033,3034,721,3035],"chemotherapy","fluorouracil","mitomycin C",{"trials":3037,"activeCount":98},[3038],{"nctId":3039,"briefTitle":3040,"status":174,"phases":3041,"primaryCompletion":3042,"completion":3043,"start":3019,"enrollment":3044,"conditions":3045,"interventions":3046},"NCT01180335","Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer",[89],"2010-12","2011-12",303,[15],[2994,3047],"Genomic driven chemotherapy",{"trials":3049,"activeCount":98},[],{"trials":3051,"activeCount":98},[],{"intervention":3053,"totalTrials":804,"cells":3054},"Cetuximab",{"EARLY_PHASE1":3055,"PHASE1":3057,"PHASE2":3070,"PHASE3":3081,"PHASE4":3094,"NA":3096},{"trials":3056,"activeCount":98},[],{"trials":3058,"activeCount":98},[3059],{"nctId":3060,"briefTitle":3061,"status":174,"phases":3062,"primaryCompletion":3063,"completion":3064,"start":3065,"enrollment":2390,"conditions":3066,"interventions":3068},"NCT02215720","Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors",[87],"2014-09-15","2016-05-04","2011-04-26",[3067],"Patients With Advanced or Metastatic Solid Tumors",[3053,3069],"Temsirolimus",{"trials":3071,"activeCount":98},[3072],{"nctId":3073,"briefTitle":3074,"status":174,"phases":3075,"primaryCompletion":3076,"start":3077,"enrollment":2390,"conditions":3078,"interventions":3079},"NCT00544349","Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery",[88],"2011-05","2006-10",[26,29],[3080,3034,721,772],"cetuximab",{"trials":3082,"activeCount":98},[3083],{"nctId":3084,"briefTitle":3085,"status":174,"phases":3086,"primaryCompletion":3087,"completion":3087,"start":3088,"enrollment":3089,"conditions":3090,"interventions":3092},"NCT01884623","Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and\u002For Metastatic Squamous Cell Head and Neck Cancer",[89],"2021-10-12","2013-11-06",82,[3091],"Head Neck Cancer Squamous Cell Recurrent",[3053,3093],"Methotrexate",{"trials":3095,"activeCount":98},[],{"trials":3097,"activeCount":98},[],{"intervention":721,"totalTrials":804,"cells":3099},{"EARLY_PHASE1":3100,"PHASE1":3102,"PHASE2":3104,"PHASE3":3114,"PHASE4":3120,"NA":3122},{"trials":3101,"activeCount":98},[],{"trials":3103,"activeCount":98},[],{"trials":3105,"activeCount":98},[3106,3110],{"nctId":3073,"briefTitle":3074,"status":174,"phases":3107,"primaryCompletion":3076,"start":3077,"enrollment":2390,"conditions":3108,"interventions":3109},[88],[26,29],[3080,3034,721,772],{"nctId":3025,"briefTitle":3026,"status":344,"phases":3111,"start":3028,"conditions":3112,"interventions":3113},[88],[3030,26,3031],[3033,3034,721,3035],{"trials":3115,"activeCount":98},[3116],{"nctId":708,"briefTitle":709,"status":174,"phases":3117,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":3118,"interventions":3119},[89],[716],[373,718,719,374,361,720,721,722,723,362],{"trials":3121,"activeCount":98},[],{"trials":3123,"activeCount":98},[],{"intervention":772,"totalTrials":804,"cells":3125},{"EARLY_PHASE1":3126,"PHASE1":3128,"PHASE2":3130,"PHASE3":3148,"PHASE4":3154,"NA":3156},{"trials":3127,"activeCount":98},[],{"trials":3129,"activeCount":98},[],{"trials":3131,"activeCount":98},[3132,3136],{"nctId":3073,"briefTitle":3074,"status":174,"phases":3133,"primaryCompletion":3076,"start":3077,"enrollment":2390,"conditions":3134,"interventions":3135},[88],[26,29],[3080,3034,721,772],{"nctId":3137,"briefTitle":3138,"status":114,"phases":3139,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":804,"conditions":3142,"interventions":3144},"NCT01715363","Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer",[88],"2014-06","2012-07",[3143],"Patients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated",[3145,3146,3147],"Oxaliplatin","Folinic Acid","Fluorouracile",{"trials":3149,"activeCount":98},[3150],{"nctId":760,"briefTitle":761,"status":174,"phases":3151,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":3152,"interventions":3153},[89],[26,767],[769,770,771,772],{"trials":3155,"activeCount":98},[],{"trials":3157,"activeCount":98},[],{"intervention":867,"totalTrials":804,"cells":3159},{"EARLY_PHASE1":3160,"PHASE1":3162,"PHASE2":3164,"PHASE3":3170,"PHASE4":3180,"NA":3182},{"trials":3161,"activeCount":98},[],{"trials":3163,"activeCount":98},[],{"trials":3165,"activeCount":98},[3166],{"nctId":856,"briefTitle":857,"status":174,"phases":3167,"primaryCompletion":859,"completion":860,"start":861,"enrollment":862,"conditions":3168,"interventions":3169},[88],[864,865],[334,867],{"trials":3171,"activeCount":98},[3172,3176],{"nctId":1803,"briefTitle":1804,"status":174,"phases":3173,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":11,"conditions":3174,"interventions":3175},[89],[1251],[867,163],{"nctId":875,"briefTitle":876,"status":174,"phases":3177,"primaryCompletion":878,"completion":878,"start":879,"enrollment":880,"conditions":3178,"interventions":3179},[89],[882],[334,867],{"trials":3181,"activeCount":98},[],{"trials":3183,"activeCount":98},[],{"intervention":3185,"totalTrials":192,"cells":3186},"rituximab",{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3202,"PHASE4":3211,"NA":3213},{"trials":3188,"activeCount":98},[],{"trials":3190,"activeCount":98},[],{"trials":3192,"activeCount":98},[3193],{"nctId":3194,"briefTitle":3195,"status":114,"phases":3196,"start":3197,"enrollment":2434,"conditions":3198,"interventions":3200},"NCT00180895","Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL\u002FL3ALL",[88],"2004-06",[3199],"Burkitt Lymphoma",[3201],"Rituximab",{"trials":3203,"activeCount":98},[3204],{"nctId":3205,"briefTitle":3206,"status":344,"phases":3207,"start":1917,"enrollment":3208,"conditions":3209,"interventions":3210},"NCT00180882","LMBA02 Protocol for Patients With a Burkitt Lymphoma",[89],260,[3199],[3185],{"trials":3212,"activeCount":98},[],{"trials":3214,"activeCount":98},[],{"intervention":374,"totalTrials":192,"cells":3216},{"EARLY_PHASE1":3217,"PHASE1":3219,"PHASE2":3221,"PHASE3":3223,"PHASE4":3233,"NA":3235},{"trials":3218,"activeCount":98},[],{"trials":3220,"activeCount":98},[],{"trials":3222,"activeCount":98},[],{"trials":3224,"activeCount":98},[3225,3229],{"nctId":708,"briefTitle":709,"status":174,"phases":3226,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":3227,"interventions":3228},[89],[716],[373,718,719,374,361,720,721,722,723,362],{"nctId":366,"briefTitle":367,"status":344,"phases":3230,"start":369,"enrollment":370,"conditions":3231,"interventions":3232},[89],[24],[351,373,374,361],{"trials":3234,"activeCount":98},[],{"trials":3236,"activeCount":98},[],{"intervention":722,"totalTrials":192,"cells":3238},{"EARLY_PHASE1":3239,"PHASE1":3241,"PHASE2":3243,"PHASE3":3245,"PHASE4":3255,"NA":3257},{"trials":3240,"activeCount":98},[],{"trials":3242,"activeCount":98},[],{"trials":3244,"activeCount":98},[],{"trials":3246,"activeCount":98},[3247,3251],{"nctId":708,"briefTitle":709,"status":174,"phases":3248,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":3249,"interventions":3250},[89],[716],[373,718,719,374,361,720,721,722,723,362],{"nctId":3084,"briefTitle":3085,"status":174,"phases":3252,"primaryCompletion":3087,"completion":3087,"start":3088,"enrollment":3089,"conditions":3253,"interventions":3254},[89],[3091],[3053,3093],{"trials":3256,"activeCount":98},[],{"trials":3258,"activeCount":98},[],{"intervention":362,"totalTrials":192,"cells":3260},{"EARLY_PHASE1":3261,"PHASE1":3263,"PHASE2":3265,"PHASE3":3267,"PHASE4":3277,"NA":3279},{"trials":3262,"activeCount":98},[],{"trials":3264,"activeCount":98},[],{"trials":3266,"activeCount":98},[],{"trials":3268,"activeCount":98},[3269,3273],{"nctId":708,"briefTitle":709,"status":174,"phases":3270,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":3271,"interventions":3272},[89],[716],[373,718,719,374,361,720,721,722,723,362],{"nctId":353,"briefTitle":354,"status":174,"phases":3274,"primaryCompletion":356,"start":357,"enrollment":358,"conditions":3275,"interventions":3276},[89],[24],[351,361,362,363,364],{"trials":3278,"activeCount":98},[],{"trials":3280,"activeCount":98},[],{"intervention":3282,"totalTrials":192,"cells":3283},"Escitalopram",{"EARLY_PHASE1":3284,"PHASE1":3286,"PHASE2":3288,"PHASE3":3290,"PHASE4":3309,"NA":3311},{"trials":3285,"activeCount":98},[],{"trials":3287,"activeCount":98},[],{"trials":3289,"activeCount":98},[],{"trials":3291,"activeCount":98},[3292,3302],{"nctId":3293,"briefTitle":3294,"status":174,"phases":3295,"primaryCompletion":3296,"completion":3296,"start":3297,"enrollment":3298,"conditions":3299,"interventions":3301},"NCT02246244","Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress",[89],"2013-03","2009-04",38,[3300],"ENT Cancer",[3282],{"nctId":3303,"briefTitle":3304,"status":344,"phases":3305,"enrollment":2645,"conditions":3306,"interventions":3308},"NCT00935675","Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment",[89],[3307],"Carcinomas",[3282],{"trials":3310,"activeCount":98},[],{"trials":3312,"activeCount":98},[],{"intervention":769,"totalTrials":136,"cells":3314},{"EARLY_PHASE1":3315,"PHASE1":3317,"PHASE2":3319,"PHASE3":3321,"PHASE4":3327,"NA":3329},{"trials":3316,"activeCount":98},[],{"trials":3318,"activeCount":98},[],{"trials":3320,"activeCount":98},[],{"trials":3322,"activeCount":98},[3323],{"nctId":760,"briefTitle":761,"status":174,"phases":3324,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":3325,"interventions":3326},[89],[26,767],[769,770,771,772],{"trials":3328,"activeCount":98},[],{"trials":3330,"activeCount":98},[],{"intervention":770,"totalTrials":136,"cells":3332},{"EARLY_PHASE1":3333,"PHASE1":3335,"PHASE2":3337,"PHASE3":3339,"PHASE4":3345,"NA":3347},{"trials":3334,"activeCount":98},[],{"trials":3336,"activeCount":98},[],{"trials":3338,"activeCount":98},[],{"trials":3340,"activeCount":98},[3341],{"nctId":760,"briefTitle":761,"status":174,"phases":3342,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":3343,"interventions":3344},[89],[26,767],[769,770,771,772],{"trials":3346,"activeCount":98},[],{"trials":3348,"activeCount":98},[],{"intervention":3350,"totalTrials":136,"cells":3351},"Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C",{"EARLY_PHASE1":3352,"PHASE1":3354,"PHASE2":3356,"PHASE3":3358,"PHASE4":3372,"NA":3374},{"trials":3353,"activeCount":98},[],{"trials":3355,"activeCount":98},[],{"trials":3357,"activeCount":98},[],{"trials":3359,"activeCount":98},[3360],{"nctId":3361,"briefTitle":3362,"status":174,"phases":3363,"primaryCompletion":3364,"completion":3365,"start":3043,"enrollment":3366,"conditions":3367,"interventions":3370},"NCT01516580","Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients",[89],"2017-06-13","2022-11-16",482,[3368,3369],"B-cell Non Hodgkin Lymphoma","Mature B-cell Leukemia Burkitt-type",[3350,3371],"Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C",{"trials":3373,"activeCount":98},[],{"trials":3375,"activeCount":98},[],{"intervention":3371,"totalTrials":136,"cells":3377},{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3384,"PHASE4":3390,"NA":3392},{"trials":3379,"activeCount":98},[],{"trials":3381,"activeCount":98},[],{"trials":3383,"activeCount":98},[],{"trials":3385,"activeCount":98},[3386],{"nctId":3361,"briefTitle":3362,"status":174,"phases":3387,"primaryCompletion":3364,"completion":3365,"start":3043,"enrollment":3366,"conditions":3388,"interventions":3389},[89],[3368,3369],[3350,3371],{"trials":3391,"activeCount":98},[],{"trials":3393,"activeCount":98},[],{"intervention":723,"totalTrials":136,"cells":3395},{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3402,"PHASE4":3408,"NA":3410},{"trials":3397,"activeCount":98},[],{"trials":3399,"activeCount":98},[],{"trials":3401,"activeCount":98},[],{"trials":3403,"activeCount":98},[3404],{"nctId":708,"briefTitle":709,"status":174,"phases":3405,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":3406,"interventions":3407},[89],[716],[373,718,719,374,361,720,721,722,723,362],{"trials":3409,"activeCount":98},[],{"trials":3411,"activeCount":98},[],{"intervention":3413,"totalTrials":136,"cells":3414},"Etoposide, Ifosfamide, Methotrexate",{"EARLY_PHASE1":3415,"PHASE1":3417,"PHASE2":3419,"PHASE3":3421,"PHASE4":3433,"NA":3435},{"trials":3416,"activeCount":98},[],{"trials":3418,"activeCount":98},[],{"trials":3420,"activeCount":98},[],{"trials":3422,"activeCount":98},[3423],{"nctId":3424,"briefTitle":3425,"status":174,"phases":3426,"start":3427,"enrollment":3428,"conditions":3429,"interventions":3431},"NCT00180908","Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children",[89],"1994-06",226,[1776,3430],"Localised High Grade Osteosarcoma of the Limbs",[3413,3432],"Doxorubicin, Methotrexate",{"trials":3434,"activeCount":98},[],{"trials":3436,"activeCount":98},[],{"intervention":3432,"totalTrials":136,"cells":3438},{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3443,"PHASE3":3445,"PHASE4":3451,"NA":3453},{"trials":3440,"activeCount":98},[],{"trials":3442,"activeCount":98},[],{"trials":3444,"activeCount":98},[],{"trials":3446,"activeCount":98},[3447],{"nctId":3424,"briefTitle":3425,"status":174,"phases":3448,"start":3427,"enrollment":3428,"conditions":3449,"interventions":3450},[89],[1776,3430],[3413,3432],{"trials":3452,"activeCount":98},[],{"trials":3454,"activeCount":98},[],{"intervention":3456,"totalTrials":136,"cells":3457},"Thyrogen, thyroid hormone withdrawal, iode 131",{"EARLY_PHASE1":3458,"PHASE1":3460,"PHASE2":3462,"PHASE3":3464,"PHASE4":3475,"NA":3477},{"trials":3459,"activeCount":98},[],{"trials":3461,"activeCount":98},[],{"trials":3463,"activeCount":98},[],{"trials":3465,"activeCount":98},[3466],{"nctId":3467,"briefTitle":3468,"status":344,"phases":3469,"start":3470,"enrollment":3471,"conditions":3472,"interventions":3474},"NCT00435851","Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients",[89],"2007-02",950,[3473],"Thyroid Cancer",[3456],{"trials":3476,"activeCount":98},[],{"trials":3478,"activeCount":98},[],{"intervention":3480,"totalTrials":136,"cells":3481},"Taxotere",{"EARLY_PHASE1":3482,"PHASE1":3484,"PHASE2":3486,"PHASE3":3488,"PHASE4":3502,"NA":3504},{"trials":3483,"activeCount":98},[],{"trials":3485,"activeCount":98},[],{"trials":3487,"activeCount":98},[],{"trials":3489,"activeCount":98},[3490],{"nctId":3491,"briefTitle":3492,"status":174,"phases":3493,"primaryCompletion":3494,"completion":3495,"start":3496,"enrollment":3497,"conditions":3498,"interventions":3500},"NCT02044354","Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer",[89],"2017-04-13","2017-12-22","2014-05-22",195,[3499],"Metastatic Castration-resistant Prostate Cancer",[3480,3501],"Jevtana",{"trials":3503,"activeCount":98},[],{"trials":3505,"activeCount":98},[],{"intervention":3501,"totalTrials":136,"cells":3507},{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3512,"PHASE3":3514,"PHASE4":3520,"NA":3522},{"trials":3509,"activeCount":98},[],{"trials":3511,"activeCount":98},[],{"trials":3513,"activeCount":98},[],{"trials":3515,"activeCount":98},[3516],{"nctId":3491,"briefTitle":3492,"status":174,"phases":3517,"primaryCompletion":3494,"completion":3495,"start":3496,"enrollment":3497,"conditions":3518,"interventions":3519},[89],[3499],[3480,3501],{"trials":3521,"activeCount":98},[],{"trials":3523,"activeCount":98},[],{"intervention":3525,"totalTrials":136,"cells":3526},"Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide",{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3533,"PHASE4":3545,"NA":3547},{"trials":3528,"activeCount":98},[],{"trials":3530,"activeCount":98},[],{"trials":3532,"activeCount":98},[],{"trials":3534,"activeCount":98},[3535],{"nctId":3536,"briefTitle":3537,"status":114,"phases":3538,"start":3539,"enrollment":3540,"conditions":3541,"interventions":3544},"NCT00162695","Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood",[89],"1995-07",400,[3542,3543],"Rhabdomyosarcoma","Malignant Soft Tissue",[3525],{"trials":3546,"activeCount":98},[],{"trials":3548,"activeCount":98},[],{"intervention":3550,"totalTrials":136,"cells":3551},"CDDP, 5 Fu",{"EARLY_PHASE1":3552,"PHASE1":3554,"PHASE2":3556,"PHASE3":3558,"PHASE4":3571,"NA":3573},{"trials":3553,"activeCount":98},[],{"trials":3555,"activeCount":98},[],{"trials":3557,"activeCount":98},[],{"trials":3559,"activeCount":98},[3560],{"nctId":3561,"briefTitle":3562,"status":174,"phases":3563,"start":3564,"enrollment":2712,"conditions":3565,"interventions":3570},"NCT00162708","Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC",[88,89],"1996-07",[3566,3567,3568,3569],"Oropharynx Cancer","Oral Cancer","Hypopharynx Cancer","Larynx Cancer",[3550],{"trials":3572,"activeCount":98},[],{"trials":3574,"activeCount":98},[],{"intervention":3576,"totalTrials":136,"cells":3577},"half cyclophosphamide",{"EARLY_PHASE1":3578,"PHASE1":3580,"PHASE2":3582,"PHASE3":3584,"PHASE4":3599,"NA":3601},{"trials":3579,"activeCount":98},[],{"trials":3581,"activeCount":98},[],{"trials":3583,"activeCount":98},[],{"trials":3585,"activeCount":98},[3586],{"nctId":3587,"briefTitle":3588,"status":174,"phases":3589,"primaryCompletion":900,"completion":3076,"start":3590,"enrollment":3591,"conditions":3592,"interventions":3594},"NCT00162656","Treatment of Mature B-cell Lymphoma\u002FLeukaemia",[89],"1996-05",848,[3593],"B-Cell Lymphoma",[3576,3595,3596,3597,3598],"without COPADM3","mini CYVE, without 3 maintenance courses","LMB B","LMB C",{"trials":3600,"activeCount":98},[],{"trials":3602,"activeCount":98},[],{"intervention":3595,"totalTrials":136,"cells":3604},{"EARLY_PHASE1":3605,"PHASE1":3607,"PHASE2":3609,"PHASE3":3611,"PHASE4":3617,"NA":3619},{"trials":3606,"activeCount":98},[],{"trials":3608,"activeCount":98},[],{"trials":3610,"activeCount":98},[],{"trials":3612,"activeCount":98},[3613],{"nctId":3587,"briefTitle":3588,"status":174,"phases":3614,"primaryCompletion":900,"completion":3076,"start":3590,"enrollment":3591,"conditions":3615,"interventions":3616},[89],[3593],[3576,3595,3596,3597,3598],{"trials":3618,"activeCount":98},[],{"trials":3620,"activeCount":98},[],{"intervention":3596,"totalTrials":136,"cells":3622},{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3627,"PHASE3":3629,"PHASE4":3635,"NA":3637},{"trials":3624,"activeCount":98},[],{"trials":3626,"activeCount":98},[],{"trials":3628,"activeCount":98},[],{"trials":3630,"activeCount":98},[3631],{"nctId":3587,"briefTitle":3588,"status":174,"phases":3632,"primaryCompletion":900,"completion":3076,"start":3590,"enrollment":3591,"conditions":3633,"interventions":3634},[89],[3593],[3576,3595,3596,3597,3598],{"trials":3636,"activeCount":98},[],{"trials":3638,"activeCount":98},[],{"intervention":3597,"totalTrials":136,"cells":3640},{"EARLY_PHASE1":3641,"PHASE1":3643,"PHASE2":3645,"PHASE3":3647,"PHASE4":3653,"NA":3655},{"trials":3642,"activeCount":98},[],{"trials":3644,"activeCount":98},[],{"trials":3646,"activeCount":98},[],{"trials":3648,"activeCount":98},[3649],{"nctId":3587,"briefTitle":3588,"status":174,"phases":3650,"primaryCompletion":900,"completion":3076,"start":3590,"enrollment":3591,"conditions":3651,"interventions":3652},[89],[3593],[3576,3595,3596,3597,3598],{"trials":3654,"activeCount":98},[],{"trials":3656,"activeCount":98},[],{"intervention":3598,"totalTrials":136,"cells":3658},{"EARLY_PHASE1":3659,"PHASE1":3661,"PHASE2":3663,"PHASE3":3665,"PHASE4":3671,"NA":3673},{"trials":3660,"activeCount":98},[],{"trials":3662,"activeCount":98},[],{"trials":3664,"activeCount":98},[],{"trials":3666,"activeCount":98},[3667],{"nctId":3587,"briefTitle":3588,"status":174,"phases":3668,"primaryCompletion":900,"completion":3076,"start":3590,"enrollment":3591,"conditions":3669,"interventions":3670},[89],[3593],[3576,3595,3596,3597,3598],{"trials":3672,"activeCount":98},[],{"trials":3674,"activeCount":98},[],{"intervention":3676,"totalTrials":136,"cells":3677},"Isolated pelvis perfusion",{"EARLY_PHASE1":3678,"PHASE1":3680,"PHASE2":3682,"PHASE3":3684,"PHASE4":3695,"NA":3697},{"trials":3679,"activeCount":98},[],{"trials":3681,"activeCount":98},[],{"trials":3683,"activeCount":98},[],{"trials":3685,"activeCount":98},[3686],{"nctId":3687,"briefTitle":3688,"status":174,"phases":3689,"primaryCompletion":416,"completion":416,"start":3690,"enrollment":3691,"conditions":3692,"interventions":3694},"NCT00949039","Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg\u002Fkg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer",[89],"2009-02",101,[3693],"Gynaecologic or Digestive Pelvic Cancer",[3676],{"trials":3696,"activeCount":98},[],{"trials":3698,"activeCount":98},[],{"intervention":1889,"totalTrials":136,"cells":3700},{"EARLY_PHASE1":3701,"PHASE1":3703,"PHASE2":3705,"PHASE3":3707,"PHASE4":3713,"NA":3715},{"trials":3702,"activeCount":98},[],{"trials":3704,"activeCount":98},[],{"trials":3706,"activeCount":98},[],{"trials":3708,"activeCount":98},[3709],{"nctId":1881,"briefTitle":1882,"status":174,"phases":3710,"primaryCompletion":1884,"completion":1884,"start":1885,"enrollment":1886,"conditions":3711,"interventions":3712},[88,89],[26],[1889,1890,1891,1539],{"trials":3714,"activeCount":98},[],{"trials":3716,"activeCount":98},[],{"intervention":1890,"totalTrials":136,"cells":3718},{"EARLY_PHASE1":3719,"PHASE1":3721,"PHASE2":3723,"PHASE3":3725,"PHASE4":3731,"NA":3733},{"trials":3720,"activeCount":98},[],{"trials":3722,"activeCount":98},[],{"trials":3724,"activeCount":98},[],{"trials":3726,"activeCount":98},[3727],{"nctId":1881,"briefTitle":1882,"status":174,"phases":3728,"primaryCompletion":1884,"completion":1884,"start":1885,"enrollment":1886,"conditions":3729,"interventions":3730},[88,89],[26],[1889,1890,1891,1539],{"trials":3732,"activeCount":98},[],{"trials":3734,"activeCount":98},[],{"intervention":1891,"totalTrials":136,"cells":3736},{"EARLY_PHASE1":3737,"PHASE1":3739,"PHASE2":3741,"PHASE3":3743,"PHASE4":3749,"NA":3751},{"trials":3738,"activeCount":98},[],{"trials":3740,"activeCount":98},[],{"trials":3742,"activeCount":98},[],{"trials":3744,"activeCount":98},[3745],{"nctId":1881,"briefTitle":1882,"status":174,"phases":3746,"primaryCompletion":1884,"completion":1884,"start":1885,"enrollment":1886,"conditions":3747,"interventions":3748},[88,89],[26],[1889,1890,1891,1539],{"trials":3750,"activeCount":98},[],{"trials":3752,"activeCount":98},[],{"intervention":3754,"totalTrials":136,"cells":3755},"Erythropoiétine",{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3760,"PHASE3":3762,"PHASE4":3772,"NA":3774},{"trials":3757,"activeCount":98},[],{"trials":3759,"activeCount":98},[],{"trials":3761,"activeCount":98},[],{"trials":3763,"activeCount":98},[3764],{"nctId":3765,"briefTitle":3766,"status":114,"phases":3767,"start":764,"enrollment":3768,"conditions":3769,"interventions":3771},"NCT00180999","Randomised Study to Compare the Effect of r-Hu-EPO Administration With Transfusion of Red Blood Cell Concentrates and Also With the Administration of Polyvitamins in Anemic and Tired Patients Presenting a Bad Prognostic in Middle Course",[89],420,[3770],"- Medico-Economic Aspects (Evaluation of Medical Costs Related to the Three Strategies and Evaluation of Cost\u002FEfficacy)",[3754],{"trials":3773,"activeCount":98},[],{"trials":3775,"activeCount":98},[],{"intervention":364,"totalTrials":136,"cells":3777},{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3784,"PHASE4":3790,"NA":3792},{"trials":3779,"activeCount":98},[],{"trials":3781,"activeCount":98},[],{"trials":3783,"activeCount":98},[],{"trials":3785,"activeCount":98},[3786],{"nctId":353,"briefTitle":354,"status":174,"phases":3787,"primaryCompletion":356,"start":357,"enrollment":358,"conditions":3788,"interventions":3789},[89],[24],[351,361,362,363,364],{"trials":3791,"activeCount":98},[],{"trials":3793,"activeCount":98},[],{"intervention":3795,"totalTrials":136,"cells":3796},"doxorubicin, ifosfamide, cisplatin",{"EARLY_PHASE1":3797,"PHASE1":3799,"PHASE2":3801,"PHASE3":3803,"PHASE4":3814,"NA":3816},{"trials":3798,"activeCount":98},[],{"trials":3800,"activeCount":98},[],{"trials":3802,"activeCount":98},[],{"trials":3804,"activeCount":98},[3805],{"nctId":3806,"briefTitle":3807,"status":344,"phases":3808,"start":3809,"enrollment":3810,"conditions":3811,"interventions":3813},"NCT00162721","The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas",[89],"2001-09",270,[3812],"Uterine Sarcoma",[3795],{"trials":3815,"activeCount":98},[],{"trials":3817,"activeCount":98},[],{"intervention":3819,"totalTrials":136,"cells":3820},"Lidocaine",{"EARLY_PHASE1":3821,"PHASE1":3823,"PHASE2":3825,"PHASE3":3827,"PHASE4":3836,"NA":3838},{"trials":3822,"activeCount":98},[],{"trials":3824,"activeCount":98},[],{"trials":3826,"activeCount":98},[],{"trials":3828,"activeCount":98},[3829],{"nctId":3830,"briefTitle":3831,"status":344,"phases":3832,"start":1575,"enrollment":2645,"conditions":3833,"interventions":3835},"NCT00181012","Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics",[89],[18,3834],"Pain",[3819],{"trials":3837,"activeCount":98},[],{"trials":3839,"activeCount":98},[],{"intervention":3047,"totalTrials":136,"cells":3841},{"EARLY_PHASE1":3842,"PHASE1":3844,"PHASE2":3846,"PHASE3":3848,"PHASE4":3854,"NA":3856},{"trials":3843,"activeCount":98},[],{"trials":3845,"activeCount":98},[],{"trials":3847,"activeCount":98},[],{"trials":3849,"activeCount":98},[3850],{"nctId":3039,"briefTitle":3040,"status":174,"phases":3851,"primaryCompletion":3042,"completion":3043,"start":3019,"enrollment":3044,"conditions":3852,"interventions":3853},[89],[15],[2994,3047],{"trials":3855,"activeCount":98},[],{"trials":3857,"activeCount":98},[],{"intervention":3859,"totalTrials":136,"cells":3860},"Hydroxyurea",{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3867,"PHASE4":3877,"NA":3879},{"trials":3862,"activeCount":98},[],{"trials":3864,"activeCount":98},[],{"trials":3866,"activeCount":98},[],{"trials":3868,"activeCount":98},[3869],{"nctId":3870,"briefTitle":3871,"status":344,"phases":3872,"start":357,"enrollment":3873,"conditions":3874,"interventions":3876},"NCT00180973","PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.",[89],520,[3875],"LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT",[3859],{"trials":3878,"activeCount":98},[],{"trials":3880,"activeCount":98},[],{"intervention":319,"totalTrials":34,"cells":3882},{"EARLY_PHASE1":3883,"PHASE1":3885,"PHASE2":3887,"PHASE3":3915,"PHASE4":3917,"NA":3919},{"trials":3884,"activeCount":98},[],{"trials":3886,"activeCount":98},[],{"trials":3888,"activeCount":98},[3889,3893,3902,3911],{"nctId":309,"briefTitle":310,"status":174,"phases":3890,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":3891,"interventions":3892},[88],[317],[319,248],{"nctId":3894,"briefTitle":3895,"status":174,"phases":3896,"primaryCompletion":3897,"completion":3897,"start":3898,"enrollment":591,"conditions":3899,"interventions":3901},"NCT02994576","Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer",[88],"2023-03","2016-12-12",[3900],"Nonsmall Cell Lung Cancer",[319],{"nctId":3903,"briefTitle":3904,"status":114,"phases":3905,"primaryCompletion":3906,"completion":3907,"start":3908,"enrollment":1365,"conditions":3909,"interventions":3910},"NCT04276376","Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors",[88],"2023-01-25","2023-12-12","2019-04-12",[2888],[319,483],{"nctId":1584,"briefTitle":1585,"status":114,"phases":3912,"primaryCompletion":1587,"completion":1587,"start":1588,"enrollment":901,"conditions":3913,"interventions":3914},[88],[15],[319,267,1591,1592],{"trials":3916,"activeCount":98},[],{"trials":3918,"activeCount":98},[],{"trials":3920,"activeCount":98},[],{"intervention":1632,"totalTrials":804,"cells":3922},{"EARLY_PHASE1":3923,"PHASE1":3925,"PHASE2":3935,"PHASE3":3945,"PHASE4":3947,"NA":3949},{"trials":3924,"activeCount":98},[],{"trials":3926,"activeCount":98},[3927],{"nctId":3928,"briefTitle":3929,"status":174,"phases":3930,"primaryCompletion":403,"completion":403,"start":3931,"enrollment":106,"conditions":3932,"interventions":3933},"NCT02040064","Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients",[87],"2014-01",[31],[3934,1632],"Gefitinib",{"trials":3936,"activeCount":98},[3937,3941],{"nctId":1619,"briefTitle":1620,"status":127,"phases":3938,"primaryCompletion":1622,"completion":1623,"start":1624,"enrollment":98,"conditions":3939,"interventions":3940},[88],[1626,1627,1628,1629,1630],[1632,70],{"nctId":1640,"briefTitle":1641,"status":174,"phases":3942,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":1645,"conditions":3943,"interventions":3944},[87,88],[190,24,1647],[70,1632],{"trials":3946,"activeCount":98},[],{"trials":3948,"activeCount":98},[],{"trials":3950,"activeCount":98},[],{"intervention":482,"totalTrials":192,"cells":3952},{"EARLY_PHASE1":3953,"PHASE1":3955,"PHASE2":3957,"PHASE3":3980,"PHASE4":3982,"NA":3984},{"trials":3954,"activeCount":98},[],{"trials":3956,"activeCount":98},[],{"trials":3958,"activeCount":98},[3959,3976],{"nctId":3960,"briefTitle":3961,"status":114,"phases":3962,"primaryCompletion":3963,"completion":3963,"start":3964,"enrollment":3965,"conditions":3966,"interventions":3974},"NCT04779151","Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab",[88],"2025-02-25","2021-04-07",51,[3967,3968,3969,33,3970,3971,3972,3973],"Urothelial Bladder Cancer","Gastric Adenocarcinoma","Gastro-oesophageal Adenocarcinoma","Biliary Tract Cancer","Platinum-sensitive Urothelial Bladder Cancer","Clear Cell Renal Cell Carcinoma","Pancreatic Ductal Adenocarcinoma",[3975,482],"Dostarlimab",{"nctId":472,"briefTitle":473,"status":114,"phases":3977,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":3978,"interventions":3979},[87,88],[479],[481,482,154,483],{"trials":3981,"activeCount":98},[],{"trials":3983,"activeCount":98},[],{"trials":3985,"activeCount":98},[],{"intervention":3034,"totalTrials":192,"cells":3987},{"EARLY_PHASE1":3988,"PHASE1":3990,"PHASE2":3992,"PHASE3":4002,"PHASE4":4004,"NA":4006},{"trials":3989,"activeCount":98},[],{"trials":3991,"activeCount":98},[],{"trials":3993,"activeCount":98},[3994,3998],{"nctId":3073,"briefTitle":3074,"status":174,"phases":3995,"primaryCompletion":3076,"start":3077,"enrollment":2390,"conditions":3996,"interventions":3997},[88],[26,29],[3080,3034,721,772],{"nctId":3025,"briefTitle":3026,"status":344,"phases":3999,"start":3028,"conditions":4000,"interventions":4001},[88],[3030,26,3031],[3033,3034,721,3035],{"trials":4003,"activeCount":98},[],{"trials":4005,"activeCount":98},[],{"trials":4007,"activeCount":98},[],{"intervention":483,"totalTrials":192,"cells":4009},{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4014,"PHASE3":4024,"PHASE4":4026,"NA":4028},{"trials":4011,"activeCount":98},[],{"trials":4013,"activeCount":98},[],{"trials":4015,"activeCount":98},[4016,4020],{"nctId":3903,"briefTitle":3904,"status":114,"phases":4017,"primaryCompletion":3906,"completion":3907,"start":3908,"enrollment":1365,"conditions":4018,"interventions":4019},[88],[2888],[319,483],{"nctId":472,"briefTitle":473,"status":114,"phases":4021,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":4022,"interventions":4023},[87,88],[479],[481,482,154,483],{"trials":4025,"activeCount":98},[],{"trials":4027,"activeCount":98},[],{"trials":4029,"activeCount":98},[],{"intervention":4031,"totalTrials":192,"cells":4032},"Vinblastine",{"EARLY_PHASE1":4033,"PHASE1":4035,"PHASE2":4050,"PHASE3":4063,"PHASE4":4065,"NA":4067},{"trials":4034,"activeCount":98},[],{"trials":4036,"activeCount":98},[4037],{"nctId":4038,"briefTitle":4039,"status":174,"phases":4040,"primaryCompletion":4041,"completion":4042,"start":4043,"enrollment":4044,"conditions":4045,"interventions":4048},"NCT01884922","Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults",[87],"2015-09-02","2016-04-28","2013-05-29",35,[4046,4047],"Refractory Low-grade Gliomas","Recurrent Low-grade Gliomas",[4049,4031],"Nilotinib",{"trials":4051,"activeCount":98},[4052],{"nctId":4053,"briefTitle":4054,"status":114,"phases":4055,"primaryCompletion":4056,"completion":4057,"start":4058,"enrollment":4059,"conditions":4060,"interventions":4061},"NCT01887522","Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults",[88],"2019-04-20","2021-04-25","2016-07-06",144,[4046,4047],[4062,4031],"Vinblastine + Nilotinib",{"trials":4064,"activeCount":98},[],{"trials":4066,"activeCount":98},[],{"trials":4068,"activeCount":98},[],{"intervention":4070,"totalTrials":192,"cells":4071},"Sunitinib",{"EARLY_PHASE1":4072,"PHASE1":4074,"PHASE2":4076,"PHASE3":4099,"PHASE4":4101,"NA":4103},{"trials":4073,"activeCount":98},[],{"trials":4075,"activeCount":98},[],{"trials":4077,"activeCount":98},[4078,4089],{"nctId":4079,"briefTitle":4080,"status":174,"phases":4081,"primaryCompletion":4082,"completion":4082,"start":4083,"enrollment":4084,"conditions":4085,"interventions":4087},"NCT02230176","Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II",[88],"2024-04","2015-02",84,[4086],"Pancreatic Neuroendocrine Carcinoma",[4070,4088],"177Lu-DOTA0-Tyr3-Octreotate",{"nctId":4090,"briefTitle":4091,"status":174,"phases":4092,"primaryCompletion":4093,"completion":4094,"start":4095,"enrollment":1505,"conditions":4096,"interventions":4098},"NCT01371201","First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma",[88],"2013-10-01","2021-04-20","2011-12-22",[4097],"Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)",[4070],{"trials":4100,"activeCount":98},[],{"trials":4102,"activeCount":98},[],{"trials":4104,"activeCount":98},[],{"intervention":3975,"totalTrials":136,"cells":4106},{"EARLY_PHASE1":4107,"PHASE1":4109,"PHASE2":4111,"PHASE3":4117,"PHASE4":4119,"NA":4121},{"trials":4108,"activeCount":98},[],{"trials":4110,"activeCount":98},[],{"trials":4112,"activeCount":98},[4113],{"nctId":3960,"briefTitle":3961,"status":114,"phases":4114,"primaryCompletion":3963,"completion":3963,"start":3964,"enrollment":3965,"conditions":4115,"interventions":4116},[88],[3967,3968,3969,33,3970,3971,3972,3973],[3975,482],{"trials":4118,"activeCount":98},[],{"trials":4120,"activeCount":98},[],{"trials":4122,"activeCount":98},[],{"intervention":4124,"totalTrials":136,"cells":4125},"Atezolizumab 1200 mg IV",{"EARLY_PHASE1":4126,"PHASE1":4128,"PHASE2":4130,"PHASE3":4144,"PHASE4":4146,"NA":4148},{"trials":4127,"activeCount":98},[],{"trials":4129,"activeCount":98},[],{"trials":4131,"activeCount":98},[4132],{"nctId":4133,"briefTitle":4134,"status":127,"phases":4135,"primaryCompletion":4136,"completion":4136,"start":4137,"enrollment":98,"conditions":4138,"interventions":4142},"NCT06713798","Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures",[88],"2025-09-15","2025-01-30",[4139,4140,4141],"Metastatic Cancer Lung","Advanced Lung Cancer","CBNPC Cancer",[4124,4143],"Tiragolumab 600 mg IV",{"trials":4145,"activeCount":98},[],{"trials":4147,"activeCount":98},[],{"trials":4149,"activeCount":98},[],{"intervention":4143,"totalTrials":136,"cells":4151},{"EARLY_PHASE1":4152,"PHASE1":4154,"PHASE2":4156,"PHASE3":4162,"PHASE4":4164,"NA":4166},{"trials":4153,"activeCount":98},[],{"trials":4155,"activeCount":98},[],{"trials":4157,"activeCount":98},[4158],{"nctId":4133,"briefTitle":4134,"status":127,"phases":4159,"primaryCompletion":4136,"completion":4136,"start":4137,"enrollment":98,"conditions":4160,"interventions":4161},[88],[4139,4140,4141],[4124,4143],{"trials":4163,"activeCount":98},[],{"trials":4165,"activeCount":98},[],{"trials":4167,"activeCount":98},[],{"intervention":4169,"totalTrials":136,"cells":4170},"Pasireotide 0.9 MG\u002FML",{"EARLY_PHASE1":4171,"PHASE1":4173,"PHASE2":4175,"PHASE3":4185,"PHASE4":4187,"NA":4189},{"trials":4172,"activeCount":98},[],{"trials":4174,"activeCount":98},[],{"trials":4176,"activeCount":98},[4177],{"nctId":4178,"briefTitle":4179,"status":114,"phases":4180,"primaryCompletion":4181,"completion":4181,"start":712,"enrollment":22,"conditions":4182,"interventions":4184},"NCT04826432","Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis",[88],"2024-02-07",[4183],"Peritoneal Carcinomatosis",[4169],{"trials":4186,"activeCount":98},[],{"trials":4188,"activeCount":98},[],{"trials":4190,"activeCount":98},[],{"intervention":905,"totalTrials":136,"cells":4192},{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4197,"PHASE3":4203,"PHASE4":4205,"NA":4207},{"trials":4194,"activeCount":98},[],{"trials":4196,"activeCount":98},[],{"trials":4198,"activeCount":98},[4199],{"nctId":897,"briefTitle":898,"status":344,"phases":4200,"start":900,"enrollment":901,"conditions":4201,"interventions":4202},[88],[903],[905,336],{"trials":4204,"activeCount":98},[],{"trials":4206,"activeCount":98},[],{"trials":4208,"activeCount":98},[],{"intervention":4210,"totalTrials":136,"cells":4211},"Bortezomid",{"EARLY_PHASE1":4212,"PHASE1":4214,"PHASE2":4216,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4213,"activeCount":98},[],{"trials":4215,"activeCount":98},[],{"trials":4217,"activeCount":98},[4218],{"nctId":4219,"briefTitle":4220,"status":114,"phases":4221,"primaryCompletion":4222,"completion":4223,"start":4224,"enrollment":4225,"conditions":4226,"interventions":4228},"NCT00346645","A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer",[88],"2007-05","2007-12","2006-06",46,[4227],"STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER",[4210],{"trials":4230,"activeCount":98},[],{"trials":4232,"activeCount":98},[],{"trials":4234,"activeCount":98},[],{"intervention":4236,"totalTrials":136,"cells":4237},"Trametinib",{"EARLY_PHASE1":4238,"PHASE1":4240,"PHASE2":4242,"PHASE3":4256,"PHASE4":4258,"NA":4260},{"trials":4239,"activeCount":98},[],{"trials":4241,"activeCount":98},[],{"trials":4243,"activeCount":98},[4244],{"nctId":4245,"briefTitle":4246,"status":174,"phases":4247,"primaryCompletion":4248,"completion":4249,"start":4250,"enrollment":2434,"conditions":4251,"interventions":4253},"NCT03244956","Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer",[88],"2022-05-23","2026-01-15","2017-12-27",[4252],"Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation",[4236,4254,4255],"Dabrafenib","rhTSH",{"trials":4257,"activeCount":98},[],{"trials":4259,"activeCount":98},[],{"trials":4261,"activeCount":98},[],{"intervention":4254,"totalTrials":136,"cells":4263},{"EARLY_PHASE1":4264,"PHASE1":4266,"PHASE2":4268,"PHASE3":4274,"PHASE4":4276,"NA":4278},{"trials":4265,"activeCount":98},[],{"trials":4267,"activeCount":98},[],{"trials":4269,"activeCount":98},[4270],{"nctId":4245,"briefTitle":4246,"status":174,"phases":4271,"primaryCompletion":4248,"completion":4249,"start":4250,"enrollment":2434,"conditions":4272,"interventions":4273},[88],[4252],[4236,4254,4255],{"trials":4275,"activeCount":98},[],{"trials":4277,"activeCount":98},[],{"trials":4279,"activeCount":98},[],{"intervention":4255,"totalTrials":136,"cells":4281},{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4286,"PHASE3":4292,"PHASE4":4294,"NA":4296},{"trials":4283,"activeCount":98},[],{"trials":4285,"activeCount":98},[],{"trials":4287,"activeCount":98},[4288],{"nctId":4245,"briefTitle":4246,"status":174,"phases":4289,"primaryCompletion":4248,"completion":4249,"start":4250,"enrollment":2434,"conditions":4290,"interventions":4291},[88],[4252],[4236,4254,4255],{"trials":4293,"activeCount":98},[],{"trials":4295,"activeCount":98},[],{"trials":4297,"activeCount":98},[],{"intervention":4299,"totalTrials":136,"cells":4300},"Dex2",{"EARLY_PHASE1":4301,"PHASE1":4303,"PHASE2":4305,"PHASE3":4315,"PHASE4":4317,"NA":4319},{"trials":4302,"activeCount":98},[],{"trials":4304,"activeCount":98},[],{"trials":4306,"activeCount":98},[4307],{"nctId":4308,"briefTitle":4309,"status":174,"phases":4310,"primaryCompletion":4311,"completion":4311,"start":4312,"enrollment":178,"conditions":4313,"interventions":4314},"NCT01159288","Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes",[88],"2015-12-19","2010-05-19",[31],[4299],{"trials":4316,"activeCount":98},[],{"trials":4318,"activeCount":98},[],{"trials":4320,"activeCount":98},[],{"intervention":4322,"totalTrials":136,"cells":4323},"Vinorelbine, cyclofosfamide",{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4328,"PHASE3":4344,"PHASE4":4346,"NA":4348},{"trials":4325,"activeCount":98},[],{"trials":4327,"activeCount":98},[],{"trials":4329,"activeCount":98},[4330],{"nctId":4331,"briefTitle":4332,"status":344,"phases":4333,"start":4334,"enrollment":4335,"conditions":4336,"interventions":4343},"NCT00180947","Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse",[88],"2003-06",210,[4337,4338,4339,4340,4341,4342],"Rhabdomyosarcomas","Neoplasms, Connective and Soft Tissue","Ewing Tumor","Osteosarcomas","Neuroblastomas","Medulloblastomas",[4322],{"trials":4345,"activeCount":98},[],{"trials":4347,"activeCount":98},[],{"trials":4349,"activeCount":98},[],{"intervention":822,"totalTrials":136,"cells":4351},{"EARLY_PHASE1":4352,"PHASE1":4354,"PHASE2":4356,"PHASE3":4362,"PHASE4":4364,"NA":4366},{"trials":4353,"activeCount":98},[],{"trials":4355,"activeCount":98},[],{"trials":4357,"activeCount":98},[4358],{"nctId":813,"briefTitle":814,"status":114,"phases":4359,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":4360,"interventions":4361},[87,88],[820],[822,337,823,824,825,151],{"trials":4363,"activeCount":98},[],{"trials":4365,"activeCount":98},[],{"trials":4367,"activeCount":98},[],{"intervention":823,"totalTrials":136,"cells":4369},{"EARLY_PHASE1":4370,"PHASE1":4372,"PHASE2":4374,"PHASE3":4380,"PHASE4":4382,"NA":4384},{"trials":4371,"activeCount":98},[],{"trials":4373,"activeCount":98},[],{"trials":4375,"activeCount":98},[4376],{"nctId":813,"briefTitle":814,"status":114,"phases":4377,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":4378,"interventions":4379},[87,88],[820],[822,337,823,824,825,151],{"trials":4381,"activeCount":98},[],{"trials":4383,"activeCount":98},[],{"trials":4385,"activeCount":98},[],{"intervention":824,"totalTrials":136,"cells":4387},{"EARLY_PHASE1":4388,"PHASE1":4390,"PHASE2":4392,"PHASE3":4398,"PHASE4":4400,"NA":4402},{"trials":4389,"activeCount":98},[],{"trials":4391,"activeCount":98},[],{"trials":4393,"activeCount":98},[4394],{"nctId":813,"briefTitle":814,"status":114,"phases":4395,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":4396,"interventions":4397},[87,88],[820],[822,337,823,824,825,151],{"trials":4399,"activeCount":98},[],{"trials":4401,"activeCount":98},[],{"trials":4403,"activeCount":98},[],{"intervention":825,"totalTrials":136,"cells":4405},{"EARLY_PHASE1":4406,"PHASE1":4408,"PHASE2":4410,"PHASE3":4416,"PHASE4":4418,"NA":4420},{"trials":4407,"activeCount":98},[],{"trials":4409,"activeCount":98},[],{"trials":4411,"activeCount":98},[4412],{"nctId":813,"briefTitle":814,"status":114,"phases":4413,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":4414,"interventions":4415},[87,88],[820],[822,337,823,824,825,151],{"trials":4417,"activeCount":98},[],{"trials":4419,"activeCount":98},[],{"trials":4421,"activeCount":98},[],{"intervention":3035,"totalTrials":136,"cells":4423},{"EARLY_PHASE1":4424,"PHASE1":4426,"PHASE2":4428,"PHASE3":4434,"PHASE4":4436,"NA":4438},{"trials":4425,"activeCount":98},[],{"trials":4427,"activeCount":98},[],{"trials":4429,"activeCount":98},[4430],{"nctId":3025,"briefTitle":3026,"status":344,"phases":4431,"start":3028,"conditions":4432,"interventions":4433},[88],[3030,26,3031],[3033,3034,721,3035],{"trials":4435,"activeCount":98},[],{"trials":4437,"activeCount":98},[],{"trials":4439,"activeCount":98},[],{"intervention":4441,"totalTrials":136,"cells":4442},"Gemox, Cetuximab",{"EARLY_PHASE1":4443,"PHASE1":4445,"PHASE2":4447,"PHASE3":4458,"PHASE4":4460,"NA":4462},{"trials":4444,"activeCount":98},[],{"trials":4446,"activeCount":98},[],{"trials":4448,"activeCount":98},[4449],{"nctId":4450,"briefTitle":4451,"status":174,"phases":4452,"primaryCompletion":4453,"completion":4453,"start":4454,"enrollment":880,"conditions":4455,"interventions":4457},"NCT00552149","Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin",[88],"2012-04","2007-10",[4456],"Advanced Biliary Cancer",[4441],{"trials":4459,"activeCount":98},[],{"trials":4461,"activeCount":98},[],{"trials":4463,"activeCount":98},[],{"intervention":4465,"totalTrials":136,"cells":4466},"Imatinib",{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4471,"PHASE3":4482,"PHASE4":4484,"NA":4486},{"trials":4468,"activeCount":98},[],{"trials":4470,"activeCount":98},[],{"trials":4472,"activeCount":98},[4473],{"nctId":4474,"briefTitle":4475,"status":344,"phases":4476,"start":4477,"enrollment":261,"conditions":4478,"interventions":4481},"NCT00180921","Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck",[88],"2004-07",[4479,4480],"Cancer of the Head and Neck","Carcinoma, Adenoid Cystic",[4465],{"trials":4483,"activeCount":98},[],{"trials":4485,"activeCount":98},[],{"trials":4487,"activeCount":98},[],{"intervention":4489,"totalTrials":136,"cells":4490},"Hydroxychloroquine",{"EARLY_PHASE1":4491,"PHASE1":4493,"PHASE2":4495,"PHASE3":4508,"PHASE4":4510,"NA":4512},{"trials":4492,"activeCount":98},[],{"trials":4494,"activeCount":98},[],{"trials":4496,"activeCount":98},[4497],{"nctId":4498,"briefTitle":4499,"status":344,"phases":4500,"primaryCompletion":4501,"completion":4501,"start":4502,"enrollment":4503,"conditions":4504,"interventions":4506},"NCT04341207","Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients",[88],"2022-04","2020-04-03",1000,[4505],"Cancer & COVID 19",[4489,4507],"Azithromycin",{"trials":4509,"activeCount":98},[],{"trials":4511,"activeCount":98},[],{"trials":4513,"activeCount":98},[],{"intervention":4507,"totalTrials":136,"cells":4515},{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4520,"PHASE3":4526,"PHASE4":4528,"NA":4530},{"trials":4517,"activeCount":98},[],{"trials":4519,"activeCount":98},[],{"trials":4521,"activeCount":98},[4522],{"nctId":4498,"briefTitle":4499,"status":344,"phases":4523,"primaryCompletion":4501,"completion":4501,"start":4502,"enrollment":4503,"conditions":4524,"interventions":4525},[88],[4505],[4489,4507],{"trials":4527,"activeCount":98},[],{"trials":4529,"activeCount":98},[],{"trials":4531,"activeCount":98},[],{"intervention":4533,"totalTrials":136,"cells":4534},"Temozolomide\u002FHycamtin",{"EARLY_PHASE1":4535,"PHASE1":4537,"PHASE2":4539,"PHASE3":4553,"PHASE4":4555,"NA":4557},{"trials":4536,"activeCount":98},[],{"trials":4538,"activeCount":98},[],{"trials":4540,"activeCount":98},[4541],{"nctId":4542,"briefTitle":4543,"status":174,"phases":4544,"primaryCompletion":4545,"completion":4546,"start":4547,"enrollment":4548,"conditions":4549,"interventions":4552},"NCT00918320","Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours",[88],"2013-10","2015-08","2009-06",129,[1775,4550,4551],"Brain Tumors","Solid Tumors",[4533],{"trials":4554,"activeCount":98},[],{"trials":4556,"activeCount":98},[],{"trials":4558,"activeCount":98},[],{"intervention":4560,"totalTrials":136,"cells":4561},"Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab",{"EARLY_PHASE1":4562,"PHASE1":4564,"PHASE2":4566,"PHASE3":4577,"PHASE4":4579,"NA":4581},{"trials":4563,"activeCount":98},[],{"trials":4565,"activeCount":98},[],{"trials":4567,"activeCount":98},[4568],{"nctId":4569,"briefTitle":4570,"status":174,"phases":4571,"primaryCompletion":4572,"completion":3365,"start":4573,"enrollment":565,"conditions":4574,"interventions":4576},"NCT01516567","Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation",[88],"2017-04","2012-04-01",[4575],"Primary Mediastinal Large B Cell Lymphoma",[4560],{"trials":4578,"activeCount":98},[],{"trials":4580,"activeCount":98},[],{"trials":4582,"activeCount":98},[],{"intervention":4584,"totalTrials":136,"cells":4585},"Cabazitaxel",{"EARLY_PHASE1":4586,"PHASE1":4588,"PHASE2":4590,"PHASE3":4602,"PHASE4":4604,"NA":4606},{"trials":4587,"activeCount":98},[],{"trials":4589,"activeCount":98},[],{"trials":4591,"activeCount":98},[4592],{"nctId":4593,"briefTitle":4594,"status":174,"phases":4595,"primaryCompletion":4596,"completion":4597,"start":4598,"enrollment":833,"conditions":4599,"interventions":4601},"NCT02115165","A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors",[88],"2022-04-29","2023-04-24","2014-07-23",[4600],"Non-seminomatous Germ-cell Tumors",[4584],{"trials":4603,"activeCount":98},[],{"trials":4605,"activeCount":98},[],{"trials":4607,"activeCount":98},[],{"intervention":4609,"totalTrials":136,"cells":4610},"Glivec",{"EARLY_PHASE1":4611,"PHASE1":4613,"PHASE2":4615,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4612,"activeCount":98},[],{"trials":4614,"activeCount":98},[],{"trials":4616,"activeCount":98},[4617],{"nctId":4618,"briefTitle":4619,"status":114,"phases":4620,"start":4621,"enrollment":4622,"conditions":4623,"interventions":4624},"NCT00180830","Glivec Phase II Pediatric Study",[88],"2003-12",36,[18],[4609,4625],"Gleevec",{"trials":4627,"activeCount":98},[],{"trials":4629,"activeCount":98},[],{"trials":4631,"activeCount":98},[],{"intervention":4625,"totalTrials":136,"cells":4633},{"EARLY_PHASE1":4634,"PHASE1":4636,"PHASE2":4638,"PHASE3":4644,"PHASE4":4646,"NA":4648},{"trials":4635,"activeCount":98},[],{"trials":4637,"activeCount":98},[],{"trials":4639,"activeCount":98},[4640],{"nctId":4618,"briefTitle":4619,"status":114,"phases":4641,"start":4621,"enrollment":4622,"conditions":4642,"interventions":4643},[88],[18],[4609,4625],{"trials":4645,"activeCount":98},[],{"trials":4647,"activeCount":98},[],{"trials":4649,"activeCount":98},[],{"intervention":668,"totalTrials":136,"cells":4651},{"EARLY_PHASE1":4652,"PHASE1":4654,"PHASE2":4656,"PHASE3":4662,"PHASE4":4664,"NA":4666},{"trials":4653,"activeCount":98},[],{"trials":4655,"activeCount":98},[],{"trials":4657,"activeCount":98},[4658],{"nctId":659,"briefTitle":660,"status":344,"phases":4659,"primaryCompletion":662,"completion":662,"start":663,"enrollment":664,"conditions":4660,"interventions":4661},[88],[666],[668,152,669],{"trials":4663,"activeCount":98},[],{"trials":4665,"activeCount":98},[],{"trials":4667,"activeCount":98},[],{"intervention":669,"totalTrials":136,"cells":4669},{"EARLY_PHASE1":4670,"PHASE1":4672,"PHASE2":4674,"PHASE3":4680,"PHASE4":4682,"NA":4684},{"trials":4671,"activeCount":98},[],{"trials":4673,"activeCount":98},[],{"trials":4675,"activeCount":98},[4676],{"nctId":659,"briefTitle":660,"status":344,"phases":4677,"primaryCompletion":662,"completion":662,"start":663,"enrollment":664,"conditions":4678,"interventions":4679},[88],[666],[668,152,669],{"trials":4681,"activeCount":98},[],{"trials":4683,"activeCount":98},[],{"trials":4685,"activeCount":98},[],{"intervention":1681,"totalTrials":136,"cells":4687},{"EARLY_PHASE1":4688,"PHASE1":4690,"PHASE2":4692,"PHASE3":4698,"PHASE4":4700,"NA":4702},{"trials":4689,"activeCount":98},[],{"trials":4691,"activeCount":98},[],{"trials":4693,"activeCount":98},[4694],{"nctId":1672,"briefTitle":1673,"status":344,"phases":4695,"primaryCompletion":1675,"start":1676,"enrollment":1677,"conditions":4696,"interventions":4697},[87,88],[1679],[1681,1682,1683,1684],{"trials":4699,"activeCount":98},[],{"trials":4701,"activeCount":98},[],{"trials":4703,"activeCount":98},[],{"intervention":1683,"totalTrials":136,"cells":4705},{"EARLY_PHASE1":4706,"PHASE1":4708,"PHASE2":4710,"PHASE3":4716,"PHASE4":4718,"NA":4720},{"trials":4707,"activeCount":98},[],{"trials":4709,"activeCount":98},[],{"trials":4711,"activeCount":98},[4712],{"nctId":1672,"briefTitle":1673,"status":344,"phases":4713,"primaryCompletion":1675,"start":1676,"enrollment":1677,"conditions":4714,"interventions":4715},[87,88],[1679],[1681,1682,1683,1684],{"trials":4717,"activeCount":98},[],{"trials":4719,"activeCount":98},[],{"trials":4721,"activeCount":98},[],{"intervention":1684,"totalTrials":136,"cells":4723},{"EARLY_PHASE1":4724,"PHASE1":4726,"PHASE2":4728,"PHASE3":4734,"PHASE4":4736,"NA":4738},{"trials":4725,"activeCount":98},[],{"trials":4727,"activeCount":98},[],{"trials":4729,"activeCount":98},[4730],{"nctId":1672,"briefTitle":1673,"status":344,"phases":4731,"primaryCompletion":1675,"start":1676,"enrollment":1677,"conditions":4732,"interventions":4733},[87,88],[1679],[1681,1682,1683,1684],{"trials":4735,"activeCount":98},[],{"trials":4737,"activeCount":98},[],{"trials":4739,"activeCount":98},[],{"intervention":4741,"totalTrials":136,"cells":4742},"Temozolomide, Cisplatinum",{"EARLY_PHASE1":4743,"PHASE1":4745,"PHASE2":4747,"PHASE3":4758,"PHASE4":4760,"NA":4762},{"trials":4744,"activeCount":98},[],{"trials":4746,"activeCount":98},[],{"trials":4748,"activeCount":98},[4749],{"nctId":4750,"briefTitle":4751,"status":174,"phases":4752,"primaryCompletion":4753,"completion":4223,"start":4754,"enrollment":12,"conditions":4755,"interventions":4757},"NCT00147160","Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents",[88],"2006-07","2003-10",[4756],"Glioma",[4741],{"trials":4759,"activeCount":98},[],{"trials":4761,"activeCount":98},[],{"trials":4763,"activeCount":98},[],{"intervention":603,"totalTrials":136,"cells":4765},{"EARLY_PHASE1":4766,"PHASE1":4768,"PHASE2":4770,"PHASE3":4776,"PHASE4":4778,"NA":4780},{"trials":4767,"activeCount":98},[],{"trials":4769,"activeCount":98},[],{"trials":4771,"activeCount":98},[4772],{"nctId":596,"briefTitle":597,"status":127,"phases":4773,"primaryCompletion":599,"completion":447,"start":600,"enrollment":98,"conditions":4774,"interventions":4775},[88],[18],[206,603,604],{"trials":4777,"activeCount":98},[],{"trials":4779,"activeCount":98},[],{"trials":4781,"activeCount":98},[],{"intervention":604,"totalTrials":136,"cells":4783},{"EARLY_PHASE1":4784,"PHASE1":4786,"PHASE2":4788,"PHASE3":4794,"PHASE4":4796,"NA":4798},{"trials":4785,"activeCount":98},[],{"trials":4787,"activeCount":98},[],{"trials":4789,"activeCount":98},[4790],{"nctId":596,"briefTitle":597,"status":127,"phases":4791,"primaryCompletion":599,"completion":447,"start":600,"enrollment":98,"conditions":4792,"interventions":4793},[88],[18],[206,603,604],{"trials":4795,"activeCount":98},[],{"trials":4797,"activeCount":98},[],{"trials":4799,"activeCount":98},[],{"intervention":4801,"totalTrials":136,"cells":4802},"ODM-201",{"EARLY_PHASE1":4803,"PHASE1":4805,"PHASE2":4807,"PHASE3":4820,"PHASE4":4822,"NA":4824},{"trials":4804,"activeCount":98},[],{"trials":4806,"activeCount":98},[],{"trials":4808,"activeCount":98},[4809],{"nctId":4810,"briefTitle":4811,"status":174,"phases":4812,"primaryCompletion":4813,"completion":4814,"start":4815,"enrollment":664,"conditions":4816,"interventions":4818},"NCT03314324","A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer",[88],"2022-01-31","2024-09-25","2017-11-29",[4817],"Metastatic Castrate-resistant Prostate (CRPC) Cancer",[4801,4819],"Enzalutamide",{"trials":4821,"activeCount":98},[],{"trials":4823,"activeCount":98},[],{"trials":4825,"activeCount":98},[],{"intervention":4819,"totalTrials":136,"cells":4827},{"EARLY_PHASE1":4828,"PHASE1":4830,"PHASE2":4832,"PHASE3":4838,"PHASE4":4840,"NA":4842},{"trials":4829,"activeCount":98},[],{"trials":4831,"activeCount":98},[],{"trials":4833,"activeCount":98},[4834],{"nctId":4810,"briefTitle":4811,"status":174,"phases":4835,"primaryCompletion":4813,"completion":4814,"start":4815,"enrollment":664,"conditions":4836,"interventions":4837},[88],[4817],[4801,4819],{"trials":4839,"activeCount":98},[],{"trials":4841,"activeCount":98},[],{"trials":4843,"activeCount":98},[],{"intervention":4845,"totalTrials":136,"cells":4846},"gemcitabine, ifosfamide, cisplatin, G-CSF",{"EARLY_PHASE1":4847,"PHASE1":4849,"PHASE2":4851,"PHASE3":4860,"PHASE4":4862,"NA":4864},{"trials":4848,"activeCount":98},[],{"trials":4850,"activeCount":98},[],{"trials":4852,"activeCount":98},[4853],{"nctId":4854,"briefTitle":4855,"status":344,"phases":4856,"start":4857,"enrollment":1918,"conditions":4858,"interventions":4859},"NCT00127049","Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors",[88],"2004-12",[1301],[4845],{"trials":4861,"activeCount":98},[],{"trials":4863,"activeCount":98},[],{"trials":4865,"activeCount":98},[],{"intervention":3146,"totalTrials":136,"cells":4867},{"EARLY_PHASE1":4868,"PHASE1":4870,"PHASE2":4872,"PHASE3":4878,"PHASE4":4880,"NA":4882},{"trials":4869,"activeCount":98},[],{"trials":4871,"activeCount":98},[],{"trials":4873,"activeCount":98},[4874],{"nctId":3137,"briefTitle":3138,"status":114,"phases":4875,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":804,"conditions":4876,"interventions":4877},[88],[3143],[3145,3146,3147],{"trials":4879,"activeCount":98},[],{"trials":4881,"activeCount":98},[],{"trials":4883,"activeCount":98},[],{"intervention":3147,"totalTrials":136,"cells":4885},{"EARLY_PHASE1":4886,"PHASE1":4888,"PHASE2":4890,"PHASE3":4896,"PHASE4":4898,"NA":4900},{"trials":4887,"activeCount":98},[],{"trials":4889,"activeCount":98},[],{"trials":4891,"activeCount":98},[4892],{"nctId":3137,"briefTitle":3138,"status":114,"phases":4893,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":804,"conditions":4894,"interventions":4895},[88],[3143],[3145,3146,3147],{"trials":4897,"activeCount":98},[],{"trials":4899,"activeCount":98},[],{"trials":4901,"activeCount":98},[],{"intervention":4903,"totalTrials":136,"cells":4904},"Oxaliplatin and irinotecan",{"EARLY_PHASE1":4905,"PHASE1":4907,"PHASE2":4909,"PHASE3":4922,"PHASE4":4924,"NA":4926},{"trials":4906,"activeCount":98},[],{"trials":4908,"activeCount":98},[],{"trials":4910,"activeCount":98},[4911],{"nctId":4912,"briefTitle":4913,"status":114,"phases":4914,"start":4334,"enrollment":2645,"conditions":4915,"interventions":4921},"NCT00180960","Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia",[88],[4916,4917,4918,4919,4920],"Colon Tumors","Rectum Tumors","Appendix Tumors","Peritoneum Tumors","Endocrine Tumors",[4903],{"trials":4923,"activeCount":98},[],{"trials":4925,"activeCount":98},[],{"trials":4927,"activeCount":98},[],{"intervention":4929,"totalTrials":136,"cells":4930},"Ipilimumab IT",{"EARLY_PHASE1":4931,"PHASE1":4933,"PHASE2":4935,"PHASE3":4950,"PHASE4":4952,"NA":4954},{"trials":4932,"activeCount":98},[],{"trials":4934,"activeCount":98},[],{"trials":4936,"activeCount":98},[4937],{"nctId":4938,"briefTitle":4939,"status":174,"phases":4940,"primaryCompletion":4941,"completion":4942,"start":4943,"enrollment":4944,"conditions":4945,"interventions":4947},"NCT02857569","A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma",[87,88],"2021-01","2022-05-20","2016-12-05",90,[4946],"Stage III\u002FIV Melanoma",[4929,4948,4949],"Ipilimumab IV","Nivolumab IV",{"trials":4951,"activeCount":98},[],{"trials":4953,"activeCount":98},[],{"trials":4955,"activeCount":98},[],{"intervention":4948,"totalTrials":136,"cells":4957},{"EARLY_PHASE1":4958,"PHASE1":4960,"PHASE2":4962,"PHASE3":4968,"PHASE4":4970,"NA":4972},{"trials":4959,"activeCount":98},[],{"trials":4961,"activeCount":98},[],{"trials":4963,"activeCount":98},[4964],{"nctId":4938,"briefTitle":4939,"status":174,"phases":4965,"primaryCompletion":4941,"completion":4942,"start":4943,"enrollment":4944,"conditions":4966,"interventions":4967},[87,88],[4946],[4929,4948,4949],{"trials":4969,"activeCount":98},[],{"trials":4971,"activeCount":98},[],{"trials":4973,"activeCount":98},[],{"intervention":4949,"totalTrials":136,"cells":4975},{"EARLY_PHASE1":4976,"PHASE1":4978,"PHASE2":4980,"PHASE3":4986,"PHASE4":4988,"NA":4990},{"trials":4977,"activeCount":98},[],{"trials":4979,"activeCount":98},[],{"trials":4981,"activeCount":98},[4982],{"nctId":4938,"briefTitle":4939,"status":174,"phases":4983,"primaryCompletion":4941,"completion":4942,"start":4943,"enrollment":4944,"conditions":4984,"interventions":4985},[87,88],[4946],[4929,4948,4949],{"trials":4987,"activeCount":98},[],{"trials":4989,"activeCount":98},[],{"trials":4991,"activeCount":98},[],{"intervention":4993,"totalTrials":136,"cells":4994},"docetaxel and samarium",{"EARLY_PHASE1":4995,"PHASE1":4997,"PHASE2":4999,"PHASE3":5009,"PHASE4":5011,"NA":5013},{"trials":4996,"activeCount":98},[],{"trials":4998,"activeCount":98},[],{"trials":5000,"activeCount":98},[5001],{"nctId":5002,"briefTitle":5003,"status":114,"phases":5004,"start":5005,"enrollment":5006,"conditions":5007,"interventions":5008},"NCT00126230","Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer",[88],"2004-01",55,[21],[4993],{"trials":5010,"activeCount":98},[],{"trials":5012,"activeCount":98},[],{"trials":5014,"activeCount":98},[],{"intervention":5016,"totalTrials":136,"cells":5017},"Anti-PD-L1 antibody atezolizumab",{"EARLY_PHASE1":5018,"PHASE1":5020,"PHASE2":5022,"PHASE3":5034,"PHASE4":5036,"NA":5038},{"trials":5019,"activeCount":98},[],{"trials":5021,"activeCount":98},[],{"trials":5023,"activeCount":98},[5024],{"nctId":5025,"briefTitle":5026,"status":344,"phases":5027,"primaryCompletion":4942,"completion":5028,"start":5029,"enrollment":5030,"conditions":5031,"interventions":5033},"NCT02992912","Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours",[88],"2024-10","2016-11-15",138,[5032],"Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )",[5016],{"trials":5035,"activeCount":98},[],{"trials":5037,"activeCount":98},[],{"trials":5039,"activeCount":98},[],{"intervention":5041,"totalTrials":136,"cells":5042},"Pravastatin",{"EARLY_PHASE1":5043,"PHASE1":5045,"PHASE2":5047,"PHASE3":5058,"PHASE4":5060,"NA":5062},{"trials":5044,"activeCount":98},[],{"trials":5046,"activeCount":98},[],{"trials":5048,"activeCount":98},[5049],{"nctId":5050,"briefTitle":5051,"status":174,"phases":5052,"primaryCompletion":5053,"completion":5053,"start":5054,"enrollment":651,"conditions":5055,"interventions":5057},"NCT01268202","Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis",[88],"2019-04-18","2010-12-17",[5056],"Fibrosis",[5041],{"trials":5059,"activeCount":98},[],{"trials":5061,"activeCount":98},[],{"trials":5063,"activeCount":98},[],{"intervention":1591,"totalTrials":136,"cells":5065},{"EARLY_PHASE1":5066,"PHASE1":5068,"PHASE2":5070,"PHASE3":5076,"PHASE4":5078,"NA":5080},{"trials":5067,"activeCount":98},[],{"trials":5069,"activeCount":98},[],{"trials":5071,"activeCount":98},[5072],{"nctId":1584,"briefTitle":1585,"status":114,"phases":5073,"primaryCompletion":1587,"completion":1587,"start":1588,"enrollment":901,"conditions":5074,"interventions":5075},[88],[15],[319,267,1591,1592],{"trials":5077,"activeCount":98},[],{"trials":5079,"activeCount":98},[],{"trials":5081,"activeCount":98},[],{"intervention":1592,"totalTrials":136,"cells":5083},{"EARLY_PHASE1":5084,"PHASE1":5086,"PHASE2":5088,"PHASE3":5094,"PHASE4":5096,"NA":5098},{"trials":5085,"activeCount":98},[],{"trials":5087,"activeCount":98},[],{"trials":5089,"activeCount":98},[5090],{"nctId":1584,"briefTitle":1585,"status":114,"phases":5091,"primaryCompletion":1587,"completion":1587,"start":1588,"enrollment":901,"conditions":5092,"interventions":5093},[88],[15],[319,267,1591,1592],{"trials":5095,"activeCount":98},[],{"trials":5097,"activeCount":98},[],{"trials":5099,"activeCount":98},[],{"intervention":4088,"totalTrials":136,"cells":5101},{"EARLY_PHASE1":5102,"PHASE1":5104,"PHASE2":5106,"PHASE3":5112,"PHASE4":5114,"NA":5116},{"trials":5103,"activeCount":98},[],{"trials":5105,"activeCount":98},[],{"trials":5107,"activeCount":98},[5108],{"nctId":4079,"briefTitle":4080,"status":174,"phases":5109,"primaryCompletion":4082,"completion":4082,"start":4083,"enrollment":4084,"conditions":5110,"interventions":5111},[88],[4086],[4070,4088],{"trials":5113,"activeCount":98},[],{"trials":5115,"activeCount":98},[],{"trials":5117,"activeCount":98},[],{"intervention":5119,"totalTrials":136,"cells":5120},"Abemaciclib",{"EARLY_PHASE1":5121,"PHASE1":5123,"PHASE2":5125,"PHASE3":5135,"PHASE4":5137,"NA":5139},{"trials":5122,"activeCount":98},[],{"trials":5124,"activeCount":98},[],{"trials":5126,"activeCount":98},[5127],{"nctId":5128,"briefTitle":5129,"status":174,"phases":5130,"primaryCompletion":5131,"completion":5131,"start":5132,"enrollment":3691,"conditions":5133,"interventions":5134},"NCT02831530","Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients",[88],"2018-02-02","2016-03-16",[15],[5119],{"trials":5136,"activeCount":98},[],{"trials":5138,"activeCount":98},[],{"trials":5140,"activeCount":98},[],{"intervention":5142,"totalTrials":136,"cells":5143},"gemcitabine, oxaliplatin",{"EARLY_PHASE1":5144,"PHASE1":5146,"PHASE2":5148,"PHASE3":5160,"PHASE4":5162,"NA":5164},{"trials":5145,"activeCount":98},[],{"trials":5147,"activeCount":98},[],{"trials":5149,"activeCount":98},[5150],{"nctId":5151,"briefTitle":5152,"status":114,"phases":5153,"completion":5154,"start":5155,"enrollment":5156,"conditions":5157,"interventions":5159},"NCT00127595","Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract",[88],"2005-04","2002-01",28,[5158],"Carcinoma, Transitional Cell",[5142],{"trials":5161,"activeCount":98},[],{"trials":5163,"activeCount":98},[],{"trials":5165,"activeCount":98},[],{"intervention":5167,"totalTrials":136,"cells":5168},"Catumaxomab 100µg",{"EARLY_PHASE1":5169,"PHASE1":5171,"PHASE2":5173,"PHASE3":5184,"PHASE4":5186,"NA":5188},{"trials":5170,"activeCount":98},[],{"trials":5172,"activeCount":98},[],{"trials":5174,"activeCount":98},[5175],{"nctId":5176,"briefTitle":5177,"status":114,"phases":5178,"primaryCompletion":5179,"completion":5179,"start":748,"enrollment":638,"conditions":5180,"interventions":5182},"NCT01784900","Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab",[88],"2016-01",[5181],"Patients With Gastric Peritoneal Carcinomatosis",[5167,5183],"Catumaxomab 140µg",{"trials":5185,"activeCount":98},[],{"trials":5187,"activeCount":98},[],{"trials":5189,"activeCount":98},[],{"intervention":5183,"totalTrials":136,"cells":5191},{"EARLY_PHASE1":5192,"PHASE1":5194,"PHASE2":5196,"PHASE3":5202,"PHASE4":5204,"NA":5206},{"trials":5193,"activeCount":98},[],{"trials":5195,"activeCount":98},[],{"trials":5197,"activeCount":98},[5198],{"nctId":5176,"briefTitle":5177,"status":114,"phases":5199,"primaryCompletion":5179,"completion":5179,"start":748,"enrollment":638,"conditions":5200,"interventions":5201},[88],[5181],[5167,5183],{"trials":5203,"activeCount":98},[],{"trials":5205,"activeCount":98},[],{"trials":5207,"activeCount":98},[],{"intervention":5209,"totalTrials":136,"cells":5210},"PD0332991",{"EARLY_PHASE1":5211,"PHASE1":5213,"PHASE2":5215,"PHASE3":5225,"PHASE4":5227,"NA":5229},{"trials":5212,"activeCount":98},[],{"trials":5214,"activeCount":98},[],{"trials":5216,"activeCount":98},[5217],{"nctId":5218,"briefTitle":5219,"status":174,"phases":5220,"primaryCompletion":5179,"completion":5179,"start":3931,"enrollment":5221,"conditions":5222,"interventions":5224},"NCT02008734","Randomized Phase II Study to Assess PD 0332991 in Breast Cancer",[88],132,[5223],"Untreated Operable Early Breast Cancer",[5209],{"trials":5226,"activeCount":98},[],{"trials":5228,"activeCount":98},[],{"trials":5230,"activeCount":98},[],{"intervention":5232,"totalTrials":136,"cells":5233},"Etoposide, carboplatin, melphalan, cisplatin, thiotepa",{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5238,"PHASE3":5249,"PHASE4":5251,"NA":5253},{"trials":5235,"activeCount":98},[],{"trials":5237,"activeCount":98},[],{"trials":5239,"activeCount":98},[5240],{"nctId":5241,"briefTitle":5242,"status":344,"phases":5243,"start":5244,"enrollment":5245,"conditions":5246,"interventions":5248},"NCT00180791","High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood",[88],"2002-07",71,[1773,4550,5247],"Neuroectodermal Tumors, Primitive",[5232],{"trials":5250,"activeCount":98},[],{"trials":5252,"activeCount":98},[],{"trials":5254,"activeCount":98},[],{"intervention":481,"totalTrials":136,"cells":5256},{"EARLY_PHASE1":5257,"PHASE1":5259,"PHASE2":5261,"PHASE3":5267,"PHASE4":5269,"NA":5271},{"trials":5258,"activeCount":98},[],{"trials":5260,"activeCount":98},[],{"trials":5262,"activeCount":98},[5263],{"nctId":472,"briefTitle":473,"status":114,"phases":5264,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":5265,"interventions":5266},[87,88],[479],[481,482,154,483],{"trials":5268,"activeCount":98},[],{"trials":5270,"activeCount":98},[],{"trials":5272,"activeCount":98},[],{"intervention":4062,"totalTrials":136,"cells":5274},{"EARLY_PHASE1":5275,"PHASE1":5277,"PHASE2":5279,"PHASE3":5285,"PHASE4":5287,"NA":5289},{"trials":5276,"activeCount":98},[],{"trials":5278,"activeCount":98},[],{"trials":5280,"activeCount":98},[5281],{"nctId":4053,"briefTitle":4054,"status":114,"phases":5282,"primaryCompletion":4056,"completion":4057,"start":4058,"enrollment":4059,"conditions":5283,"interventions":5284},[88],[4046,4047],[4062,4031],{"trials":5286,"activeCount":98},[],{"trials":5288,"activeCount":98},[],{"trials":5290,"activeCount":98},[],{"intervention":568,"totalTrials":136,"cells":5292},{"EARLY_PHASE1":5293,"PHASE1":5295,"PHASE2":5301,"PHASE3":5303,"PHASE4":5305,"NA":5307},{"trials":5294,"activeCount":98},[],{"trials":5296,"activeCount":98},[5297],{"nctId":559,"briefTitle":560,"status":174,"phases":5298,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":5299,"interventions":5300},[87],[479],[206,267,568],{"trials":5302,"activeCount":98},[],{"trials":5304,"activeCount":98},[],{"trials":5306,"activeCount":98},[],{"trials":5308,"activeCount":98},[],{"intervention":5310,"totalTrials":136,"cells":5311},"Tarceva",{"EARLY_PHASE1":5312,"PHASE1":5314,"PHASE2":5326,"PHASE3":5328,"PHASE4":5330,"NA":5332},{"trials":5313,"activeCount":98},[],{"trials":5315,"activeCount":98},[5316],{"nctId":5317,"briefTitle":5318,"status":174,"phases":5319,"start":5320,"enrollment":5321,"conditions":5322,"interventions":5325},"NCT00418327","Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma",[87],"2005-06",48,[5323,5324],"Malignant Brain Tumor","Brain Stem Glioma,",[5310],{"trials":5327,"activeCount":98},[],{"trials":5329,"activeCount":98},[],{"trials":5331,"activeCount":98},[],{"trials":5333,"activeCount":98},[],{"intervention":518,"totalTrials":136,"cells":5335},{"EARLY_PHASE1":5336,"PHASE1":5338,"PHASE2":5344,"PHASE3":5346,"PHASE4":5348,"NA":5350},{"trials":5337,"activeCount":98},[],{"trials":5339,"activeCount":98},[5340],{"nctId":509,"briefTitle":510,"status":174,"phases":5341,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":5342,"interventions":5343},[87],[516],[518,40],{"trials":5345,"activeCount":98},[],{"trials":5347,"activeCount":98},[],{"trials":5349,"activeCount":98},[],{"trials":5351,"activeCount":98},[],{"intervention":3069,"totalTrials":136,"cells":5353},{"EARLY_PHASE1":5354,"PHASE1":5356,"PHASE2":5362,"PHASE3":5364,"PHASE4":5366,"NA":5368},{"trials":5355,"activeCount":98},[],{"trials":5357,"activeCount":98},[5358],{"nctId":3060,"briefTitle":3061,"status":174,"phases":5359,"primaryCompletion":3063,"completion":3064,"start":3065,"enrollment":2390,"conditions":5360,"interventions":5361},[87],[3067],[3053,3069],{"trials":5363,"activeCount":98},[],{"trials":5365,"activeCount":98},[],{"trials":5367,"activeCount":98},[],{"trials":5369,"activeCount":98},[],{"intervention":530,"totalTrials":136,"cells":5371},{"EARLY_PHASE1":5372,"PHASE1":5374,"PHASE2":5380,"PHASE3":5382,"PHASE4":5384,"NA":5386},{"trials":5373,"activeCount":98},[],{"trials":5375,"activeCount":98},[5376],{"nctId":520,"briefTitle":521,"status":344,"phases":5377,"primaryCompletion":523,"start":524,"enrollment":525,"conditions":5378,"interventions":5379},[87],[516,527],[529,530,531],{"trials":5381,"activeCount":98},[],{"trials":5383,"activeCount":98},[],{"trials":5385,"activeCount":98},[],{"trials":5387,"activeCount":98},[],{"intervention":531,"totalTrials":136,"cells":5389},{"EARLY_PHASE1":5390,"PHASE1":5392,"PHASE2":5398,"PHASE3":5400,"PHASE4":5402,"NA":5404},{"trials":5391,"activeCount":98},[],{"trials":5393,"activeCount":98},[5394],{"nctId":520,"briefTitle":521,"status":344,"phases":5395,"primaryCompletion":523,"start":524,"enrollment":525,"conditions":5396,"interventions":5397},[87],[516,527],[529,530,531],{"trials":5399,"activeCount":98},[],{"trials":5401,"activeCount":98},[],{"trials":5403,"activeCount":98},[],{"trials":5405,"activeCount":98},[],{"intervention":1759,"totalTrials":136,"cells":5407},{"EARLY_PHASE1":5408,"PHASE1":5410,"PHASE2":5416,"PHASE3":5418,"PHASE4":5420,"NA":5422},{"trials":5409,"activeCount":98},[],{"trials":5411,"activeCount":98},[5412],{"nctId":1750,"briefTitle":1751,"status":174,"phases":5413,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":5414,"interventions":5415},[87],[1757],[1759,1760],{"trials":5417,"activeCount":98},[],{"trials":5419,"activeCount":98},[],{"trials":5421,"activeCount":98},[],{"trials":5423,"activeCount":98},[],{"intervention":5425,"totalTrials":136,"cells":5426},"Adalimumab",{"EARLY_PHASE1":5427,"PHASE1":5429,"PHASE2":5440,"PHASE3":5442,"PHASE4":5444,"NA":5446},{"trials":5428,"activeCount":98},[],{"trials":5430,"activeCount":98},[5431],{"nctId":5432,"briefTitle":5433,"status":127,"phases":5434,"primaryCompletion":5435,"completion":5435,"start":5436,"enrollment":98,"conditions":5437,"interventions":5439},"NCT02516774","A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers",[87],"2015-12","2014-12",[5438],"Anaplastic Thyroid Cancers",[5425],{"trials":5441,"activeCount":98},[],{"trials":5443,"activeCount":98},[],{"trials":5445,"activeCount":98},[],{"trials":5447,"activeCount":98},[],{"intervention":5449,"totalTrials":136,"cells":5450},"Topotecan, Temozolomide",{"EARLY_PHASE1":5451,"PHASE1":5453,"PHASE2":5463,"PHASE3":5465,"PHASE4":5467,"NA":5469},{"trials":5452,"activeCount":98},[],{"trials":5454,"activeCount":98},[5455],{"nctId":5456,"briefTitle":5457,"status":174,"phases":5458,"conditions":5459,"interventions":5462},"NCT00412503","Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents",[87],[5460,5461],"Refractory Tumors","Malignant Tumors",[5449],{"trials":5464,"activeCount":98},[],{"trials":5466,"activeCount":98},[],{"trials":5468,"activeCount":98},[],{"trials":5470,"activeCount":98},[],{"intervention":3934,"totalTrials":136,"cells":5472},{"EARLY_PHASE1":5473,"PHASE1":5475,"PHASE2":5481,"PHASE3":5483,"PHASE4":5485,"NA":5487},{"trials":5474,"activeCount":98},[],{"trials":5476,"activeCount":98},[5477],{"nctId":3928,"briefTitle":3929,"status":174,"phases":5478,"primaryCompletion":403,"completion":403,"start":3931,"enrollment":106,"conditions":5479,"interventions":5480},[87],[31],[3934,1632],{"trials":5482,"activeCount":98},[],{"trials":5484,"activeCount":98},[],{"trials":5486,"activeCount":98},[],{"trials":5488,"activeCount":98},[],{"intervention":4049,"totalTrials":136,"cells":5490},{"EARLY_PHASE1":5491,"PHASE1":5493,"PHASE2":5499,"PHASE3":5501,"PHASE4":5503,"NA":5505},{"trials":5492,"activeCount":98},[],{"trials":5494,"activeCount":98},[5495],{"nctId":4038,"briefTitle":4039,"status":174,"phases":5496,"primaryCompletion":4041,"completion":4042,"start":4043,"enrollment":4044,"conditions":5497,"interventions":5498},[87],[4046,4047],[4049,4031],{"trials":5500,"activeCount":98},[],{"trials":5502,"activeCount":98},[],{"trials":5504,"activeCount":98},[],{"trials":5506,"activeCount":98},[],{"intervention":123,"totalTrials":136,"cells":5508},{"EARLY_PHASE1":5509,"PHASE1":5511,"PHASE2":5517,"PHASE3":5519,"PHASE4":5521,"NA":5523},{"trials":5510,"activeCount":98},[],{"trials":5512,"activeCount":98},[5513],{"nctId":112,"briefTitle":113,"status":114,"phases":5514,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":5515,"interventions":5516},[87],[121],[110,50,123],{"trials":5518,"activeCount":98},[],{"trials":5520,"activeCount":98},[],{"trials":5522,"activeCount":98},[],{"trials":5524,"activeCount":98},[],{"intervention":134,"totalTrials":136,"cells":5526},{"EARLY_PHASE1":5527,"PHASE1":5529,"PHASE2":5535,"PHASE3":5537,"PHASE4":5539,"NA":5541},{"trials":5528,"activeCount":98},[],{"trials":5530,"activeCount":98},[5531],{"nctId":125,"briefTitle":126,"status":127,"phases":5532,"primaryCompletion":129,"completion":129,"start":130,"enrollment":98,"conditions":5533,"interventions":5534},[87],[132],[134,50,110,135],{"trials":5536,"activeCount":98},[],{"trials":5538,"activeCount":98},[],{"trials":5540,"activeCount":98},[],{"trials":5542,"activeCount":98},[],{"intervention":135,"totalTrials":136,"cells":5544},{"EARLY_PHASE1":5545,"PHASE1":5547,"PHASE2":5553,"PHASE3":5555,"PHASE4":5557,"NA":5559},{"trials":5546,"activeCount":98},[],{"trials":5548,"activeCount":98},[5549],{"nctId":125,"briefTitle":126,"status":127,"phases":5550,"primaryCompletion":129,"completion":129,"start":130,"enrollment":98,"conditions":5551,"interventions":5552},[87],[132],[134,50,110,135],{"trials":5554,"activeCount":98},[],{"trials":5556,"activeCount":98},[],{"trials":5558,"activeCount":98},[],{"trials":5560,"activeCount":98},[],{"intervention":3011,"totalTrials":136,"cells":5562},{"EARLY_PHASE1":5563,"PHASE1":5565,"PHASE2":5571,"PHASE3":5573,"PHASE4":5575,"NA":5577},{"trials":5564,"activeCount":98},[],{"trials":5566,"activeCount":98},[5567],{"nctId":3001,"briefTitle":3002,"status":344,"phases":5568,"primaryCompletion":3004,"completion":3005,"start":3006,"enrollment":3007,"conditions":5569,"interventions":5570},[87],[3009],[3011,2994],{"trials":5572,"activeCount":98},[],{"trials":5574,"activeCount":98},[],{"trials":5576,"activeCount":98},[],{"trials":5578,"activeCount":98},[],{"intervention":279,"totalTrials":136,"cells":5580},{"EARLY_PHASE1":5581,"PHASE1":5583,"PHASE2":5589,"PHASE3":5591,"PHASE4":5593,"NA":5595},{"trials":5582,"activeCount":98},[],{"trials":5584,"activeCount":98},[5585],{"nctId":269,"briefTitle":270,"status":114,"phases":5586,"primaryCompletion":272,"completion":273,"start":274,"enrollment":16,"conditions":5587,"interventions":5588},[87],[276],[70,278,248,279],{"trials":5590,"activeCount":98},[],{"trials":5592,"activeCount":98},[],{"trials":5594,"activeCount":98},[],{"trials":5596,"activeCount":98},[],{"intervention":580,"totalTrials":136,"cells":5598},{"EARLY_PHASE1":5599,"PHASE1":5601,"PHASE2":5607,"PHASE3":5609,"PHASE4":5611,"NA":5613},{"trials":5600,"activeCount":98},[],{"trials":5602,"activeCount":98},[5603],{"nctId":570,"briefTitle":571,"status":174,"phases":5604,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":5605,"interventions":5606},[87],[578],[580,206],{"trials":5608,"activeCount":98},[],{"trials":5610,"activeCount":98},[],{"trials":5612,"activeCount":98},[],{"trials":5614,"activeCount":98},[],{"intervention":5616,"totalTrials":136,"cells":5617},"Bortezomib",{"EARLY_PHASE1":5618,"PHASE1":5620,"PHASE2":5630,"PHASE3":5632,"PHASE4":5634,"NA":5636},{"trials":5619,"activeCount":98},[],{"trials":5621,"activeCount":98},[5622],{"nctId":5623,"briefTitle":5624,"status":174,"phases":5625,"primaryCompletion":5626,"completion":5626,"start":3042,"enrollment":3007,"conditions":5627,"interventions":5629},"NCT02220049","Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors",[87],"2013-11",[5628],"Advanced or Metastatic Solid Tumors",[5616],{"trials":5631,"activeCount":98},[],{"trials":5633,"activeCount":98},[],{"trials":5635,"activeCount":98},[],{"trials":5637,"activeCount":98},[],{"intervention":5639,"totalTrials":136,"cells":5640},"TSH stimulation",{"EARLY_PHASE1":5641,"PHASE1":5643,"PHASE2":5645,"PHASE3":5647,"PHASE4":5649,"NA":5651},{"trials":5642,"activeCount":98},[],{"trials":5644,"activeCount":98},[],{"trials":5646,"activeCount":98},[],{"trials":5648,"activeCount":98},[],{"trials":5650,"activeCount":98},[],{"trials":5652,"activeCount":98},[5653],{"nctId":5654,"briefTitle":5655,"status":114,"phases":5656,"primaryCompletion":39,"completion":39,"start":1488,"enrollment":34,"conditions":5657,"interventions":5659},"NCT01403324","Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer",[91],[3473,5658],"Metastases",[5639]]